

Curriculum Vitae

Diana V. Do, M.D.

Diana Do, MD

Personal Information

Address:

Byers Eye Institute
Department of Ophthalmology
Stanford University School of Medicine
2370 Watson Court
Suite #228
Palo Alto, California 94303-3216
Phone: 650-725-7245

E-mail: dianado@stanford.edu

Present Academic Rank and Positions

01/2017-now **Professor**, Medical Center Line
Byers Eye Institute
Department of Ophthalmology
Stanford University

01/2019-now **Vice Chair of Clinical Affairs**
Byers Eye Institute
Department of Ophthalmology
Stanford University

09/2021-now **Clinic Chief for Ophthalmology**
Stanford Health Care

01/2018-now **Physician Improvement Leader**
Byers Eye Institute
Department of Ophthalmology
Stanford University

Prior Professional Appointments

01/2015-12/2016 **Professor of Ophthalmology**
Vice-Chair for Education
Director of Carl Camras Center for Innovative Clinical Research
Director of Ophthalmology Residency Training Program
Director of Retina Fellowship Training Program
Truhlsen Eye Institute
Department of Ophthalmology and Visual Sciences

University of Nebraska College of Medicine
Omaha, Nebraska

02/2013-12/2014 **Associate Professor of Ophthalmology**
Vice-Chair for Education
Director of Carl Camras Center for Innovative Clinical Research
Director of Ophthalmology Residency Training Program
Truhlsen Eye Institute
Department of Ophthalmology and Visual Sciences
University of Nebraska College of Medicine
Omaha, Nebraska

01/2011-01/2013 **Associate Professor of Ophthalmology**
Head of the Retina Fellowship Training Program
The Wilmer Eye Institute
The Johns Hopkins University School of Medicine
Baltimore, Maryland

07/2005-12/2010 **Assistant Professor of Ophthalmology**
Assistant Head of the Retina Fellowship Training Program
The Wilmer Eye Institute
The Johns Hopkins University School of Medicine
Baltimore, Maryland

Education and Training

Year	Degree	Institution	Discipline
09/1987 - 06/1991		Lowell High School San Francisco, California	Arts and Sciences
09/1991 - 05/1995	B.A.	University of California, Berkeley Berkeley, California <i>Summa Cum Laude</i> <i>Phi Beta Kappa</i>	Molecular and Cell Biology
09/1995 - 05/1999	M.D.	University of California San Francisco San Francisco, California <i>University of California Regents Scholar</i> <i>Alpha Omega Alpha</i>	Doctor of Medicine
07/1999 - 06/2000	Internship	Massachusetts General Hospital Harvard Medical School Boston, Massachusetts	Internal Medicine
07/2000 - 06/2003	Residency	Wilmer Eye Institute The Johns Hopkins University School of Medicine Baltimore, Maryland	Ophthalmology
07/ 2003 -	Fellowship	Wilmer Eye Institute	Retina

Honors and Awards (Since Training)

- 2007 International Michelson Symposium, **Young Investigator Award**.
Competitive research grant given to young investigators.
- 2008 American Academy of Ophthalmology **Achievement Award**. National
award given for contributions and service.
- 2010 **President's Award**, Maryland Society of Eye Physicians and Surgeons.
Award given for leadership, significant contribution, and service.
- 2010-2013 **Board Member**, Maryland Society of Eye Physicians and Surgeons
- 2010 American Academy of Ophthalmology "**Best Retina Paper**" at Annual
Meeting for my paper presentation on "VEGF Trap-Eye for Diabetic
Macular Edema: The DA VINCI Study"
- 2010 **William Evans Bruner, MD Lectureship in Ophthalmology**, Case
Western University School of Medicine, Cleveland, Ohio
- 2016 **Honor Award**, American Society of Retina Specialists
- 2018 **Faculty Teaching Award, Byers Eye Institute, Stanford University
School of Medicine**
Awarded by residents to honor a faculty physician for outstanding teaching
and mentorship
- 2018 **San Francisco Bay Area's Top Doctors**
Nominated by peers as one of the top ophthalmologists in the Bay Area
- 2019 **San Francisco Bay Area's Top Doctors**
Nominated by peers as one of the top ophthalmologists in the Bay Area
- 2020 **San Francisco Bay Area's Top Doctors**
Nominated by peers as one of the top ophthalmologists in the Bay Area
- 2020 **Senior Honor Award**, American Society of Retina Specialists
- 2021 **San Francisco Bay Area's Top Doctors**
Nominated by peers as one of the top ophthalmologists in the Bay Area
- 2021 **The Ophthalmologist Power List**
Chosen by peers as one of the top 100 female ophthalmologists

Scholarly Publications

All Peer-review journal articles (Total: 164; Total at Stanford: 52)

First or last author peer-review articles (Total: 51; Total at Stanford: 21)

Original research first or last author peer-review articles (Total: 51; Total at Stanford: 21)

1. **Do DV**, Nguyen QD, Rismondo V. "Reversible Cortical Blindness in Preeclampsia."
American Journal of Ophthalmology 2002;134:916-918.
2. **Do DV**, Bressler NM, Bressler SB. "Large submacular hemorrhages after verteporfin
therapy." American Journal of Ophthalmology. 2004;137(3)558-560.

3. **Do DV**, Shah MS, Sung JU, Haller JA, Nguyen QD. "Persistent diabetic macular edema is associated with elevated hemoglobin A1c." *American Journal of Ophthalmology* 2005;139(4):620-623.
4. **Do DV**, Nguyen QD, Bressler NM, Solomon SD, Schachat AP, Melia M, Bressler SB. Hemoglobin A1c awareness among patients receiving care at a tertiary ophthalmic center. *American Journal of Ophthalmology* 2006;141(5):951-953.
5. **Do DV**, Cho M, Nguyen QD, Shah SM, Handa JT, Campochiaro PA, Zimmer-Galler I, Sung J, Haller JA. Impact of optical coherence tomography on surgical decision making for epiretinal membranes and vitreomacular traction. *Retina* 2007;27(5):552-6.
6. **Do DV**, Nguyen QD, Shah SM, Browning DJ, Haller JA, Chu K, Yang K, Cederbaum J, Vitti RL, Ingerman A, Campochiaro PA. An exploratory study of safety, tolerability, and bioactivity of a single intravitreal injection of VEGF Trap eye for patients with diabetic macular edema. *British J Ophthalmology* 2009 Feb;93(2):144-9.
7. Sabet-Peyman EJ, Nguyen QD, **Do DV**. Cystoid macular edema responds to intravitreal triamcinolone and rebounds after intravitreal bevacizumab. *Ophthalmic Surg Lasers Imaging*. 2009 Jul-Aug;40(4):413-5.
8. Sabet-Peyman EJ, Heussen FM, Thorne JE, Casparis H, Patel SJ, **Do DV**. Progression of macular ischemia following intravitreal bevacizumab. *Ophthalmic Surg Lasers Imaging*. 2009 May-Jun;40(3):316-8.
9. Khurana RN, Leder HA, Nguyen QD, **Do DV**. Enterococcus casseliflavus Endophthalmitis associated with a Horse tail Injury. *Arch Ophthalmol*. 2009 Nov;127(11):1551-2.
10. Fallano KA, Ibrahim M, Nguyen QD, **Do DV**. Progressive changes from idiopathic macular telangiectasia seen with spectral domain optical coherence tomography. *Can J Ophthalmol*. 2010 Dec 8;45(6):1-2.
11. Ko FS, Sohn JH, **Do DV**, Resolution of Macular Edema in Radiation Retinopathy After Intravenous Diuresis. *Retina Cases and Brief Reports* ,2010(2):174-7
12. **Do DV**, Schmidt-Erfurth U, Gonzalez VH, Gordon CM, Tolentino M, Berliner AJ, Vitti R, Rückert R, Sandbrink R, Stein D, Ke Yang K, Beckmann K, Heier JS. The DA VINCI Study: Phase 2 Primary Results of VEGF Trap-Eye in Patients with Diabetic Macular Edema. *Ophthalmology*, 2011;118(9):1819-1826.
13. Hatf E, Ibrahim, Nguyen QD, **Do DV**. Diagnostic and therapeutic challenges. Neovascular age-related macular degeneration with pigment epithelial detachment. *Retina* 2011 Jun;31(6):1218-1223
14. Chen LY, Kesen MR, Ghafourian A, Nguyen QD, Eberhart CG, **Do DV**. Isolated endogenous Nocardia endophthalmitis after immunosuppression. *J Ophthalmic Inflamm Infect*. 2012 Sep;2(3):141-143
15. **Do DV**, Gower EW, Cassard SD, Boyer D, Bressler NM, Bressler SB, Heier JS, Jefferys JL, Singerman LJ, Solomon SD. Detection of new-onset choroidal

neovascularization using optical coherence tomography: the AMD DOC Study. *Ophthalmology*. 2012 Apr;119(4):771-8.

16. **Do DV**, Nguyen QD, Boyer D, Schmidt-Erfurth U, Brown DM, Vitti R, Berliner AJ, Gao B, Zeitz O, Ruckert R, Schmelter T, Sandbrink R, Heier JS; DAVINCI Study Group*. One-Year Outcomes of the DA VINCI Study of VEGF Trap-Eye in Eyes with Diabetic Macular Edema. *Ophthalmology*. 2012 Aug;119(8):1658-65.

17. Paskowitz DM, Nguyen QD, Gehlbach P, Handa JT, Solomon S, Stark W, Shaikh O, Semba C, Gadek TR, **Do DV**. Safety, tolerability, and bioavailability of topical SAR 1118, a novel antagonist of lymphocyte function-associated antigen-1: a phase 1b study. *Eye (Lond)*. 2012 Apr 27. doi: 10.1038/eye.2012.68.

18. **Do DV**, Nguyen QD, Khwaja AA, Channa R, Sepah YJ, Sophie R, Hafiz G, Campochiaro PA; for the READ-2 Study Group. Ranibizumab for Edema of the Macula in Diabetes Study: 3-Year Outcomes and the Need for Prolonged Frequent Treatment. *JAMA Ophthalmol*. 2013 Feb;131(2):139-45.

19. **Do DV**, Greenwald L, Ibrahim M, Sepah Y, Nguyen QD. Choroidal neovascularization regression on fluorescein angiography after VEGF blockade. *Case Rep Ophthalmol*. 2012 Sep;3(3):384-8.

20. Nguyen QD, Ibrahim MA, Watters A, Bittencourt M, Yohannan J, Sepah YJ, Dunn JP, Naor J, Shams N, Shaikh O, Leder HA, **Do DV**. Ocular tolerability and efficacy of intravitreal and subconjunctival injections of sirolimus in patients with non-infectious uveitis: primary 6-month results of the SAVE Study. *J Ophthalmic Inflamm Infect*. 2013 Feb 11;3(1):32.

21. **Do DV**, Pieramici DJ, Van Lookeren Campagne M, Beers T, Friesenhahn M, Zhang Y, Strauss EC; For The Phase Ia Investigators. A Phase Ia Dose-Escalation Study Of The Anti-Factor D Monoclonal Antibody Fragment Fcfd4514s In Patients With Geographic Atrophy. *Retina*. 2014;34(2):313-320

22. **Do DV**, Bressler SB, Cassard SD, Gower EW, Tabandeh H, Jefferys JL, Bressler NM. Ranibizumab For Macular Telangiectasia Type 2 In The Absence Of Subretinal Neovascularization. *Retina*. 2014 Oct;34(10):2063-71.

23. Gonzalez VH, Boyer DS, Schmidt-Erfurth U, Heier JS, Gordon C, Benz MS, Marcus DM, Sabates NR, Vitti R, Kazmi H, Berliner AJ, Soo Y, Zhu X, Moini H, Zeitz O, Sandbrink R, **Do DV**. Microperimetric assessment of retinal sensitivity in eyes with diabetic macular edema from a phase 2 study of intravitreal aflibercept. *Retina*. 2015 Apr;35(4):687-94

24. **Do DV**, Sepah YJ, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus DM, Halperin L, Sadiq MA, Rajagopalan N, Campochiaro PA, Nguyen QD. Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the macula in Diabetes-Protocol 3 with high dose). *Eye (Lond)*. 2015 Dec;29(12):1538-44.

25. **Do DV**, Nguyen QD, Vitti R, Berliner AJ, Gibson A, Saroj N, Soo Y, Boyer DS.

Intravitreal Aflibercept Injection in Diabetic Macular Edema Patients with and without Prior Anti-Vascular Endothelial Growth Factor Treatment: Outcomes from the Phase 3 Program. *Ophthalmology*. 2016 Apr;123(4):850-7.

26. Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, Nguyen QD, **Do DV**; READ-3 Study Group. Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study. *Ophthalmology*. 2016 Dec;123(12):2581-2587.

27. Sepah YJ, Sadiq MA, Boyer D, Callanan D, Gallemore R, Bennett M, Marcus D, Halperin L, Hassan M, Campochiaro PA, Nguyen QD, **Do DV**; READ-3 Study Group. Twenty-four-Month Outcomes of the Ranibizumab for Edema of the Macula in Diabetes - Protocol 3 with High Dose (READ-3) Study. *Ophthalmology*. 2016 Dec;123(12):2581-2587. doi: 10.1016/j.ophtha.2016.08.040. Epub 2016 Oct 1.

28. Arkfeld D, Rhoades W, Baldwin A, **Do DV**. A case of complex macula-off retinal detachment following traumatic globe rupture. *Am J Ophthalmol Case Rep*. 2016 Nov 19;6:33-34. doi: 10.1016/j.ajoc.2016.11.002. eCollection 2017 Jun

29. Shields RA, Smith SJ, Pan CK, **Do DV**. Endogenous klebsiella pneumoniae endophthalmitis in Northern California. *Retina*. 2019 Mar;39(3):614-620. doi: 10.1097/IAE.0000000000001994.PMID: 29232335.

30. Nguyen QD, Merrill PT, Sepah YJ, Ibrahim MA, Banker A, Leonardi A, Chernock M, Mudumba S, **Do DV**. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies. *Ophthalmology*. 2018 Jul 27. pii: S0161-6420(17)33538-8. doi: 10.1016/j.ophtha.2018.06.015.

31. Sarwar S, Hassan M, Soliman MK, Halim MS, Sadiq MA, Afridi R, Agarwal A, **Do DV**. Diurnal variation of choriocapillaris vessel flow density in normal subjects measured using optical coherence tomography angiography. *Int J Retina Vitreous*. 2018 Oct 10;4:37. doi: 10.1186/s40942-018-0140-0. eCollection 2018.PMID: 30338130

32. Hassan M, Nguyen NV, Halim MS, Afridi R, Sadiq MA, Karkhur S, Vigil E, Karabekirogullari S, Nguyen QD, **Do DV**. Effect of vitreomacular adhesion on the treatment outcome in the STOP-Uveitis clinical trial for non-infectious uveitis. *J Ophthalmic Inflamm Infect*. 2019 Jul 19;9(1):12. doi: 10.1186/s12348-019-0179-6.PMID: 31325001.

33. Nguyen QD, Sepah YJ, Berger B, Brown D, **Do DV**. Primary outcomes of the VID1 study: phase 2, double-masked, randomized, active-controlled study of ASP8232 for diabetic macular edema. *Int J Retina Vitreous*. 2019 Aug 1;5:28. doi: 10.1186/s40942-019-0178-7. eCollection 2019.PMID: 31388454.

34. Yeh S, Kurup SK, Wang RC, Foster CS, Noronha G, Nguyen QD, **Do DV**. Suprachoroidal injection of triamcinolone acetonide, CLS-TA for macular edema due to noninfectious uveitis: A Randomized, Phase 2 Study (DOGWOOD). *Retina*. 2019 Oct;39(10):1880-1888. doi: 10.1097/IAE.0000000000002279.PMID: 30113933.

35. Nguyen NV, Vigil EM, Hassan M, Halim MS, Baluyot SC, Guzman HA, Afridi R, **Do DV**. Comparison on montage with conventional stereoscopic seven-field photographs for assessment of ETDRS diabetic retinopathy severity. *Int J Retina Vitreous*. 2019 Dec 13;5:51. doi: 10.1186/s40942-019-0201-z. eCollection 2019.PMID: 31890280.
36. **Do DV**, Rhoades W, Nguyen QD. Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration. *Retina*. 2020 Apr;40(4):643-647.
37. Carter KL, **Do DV**. Hydroxychloroquine-induced Retinal Toxicity. *J Rheumatol*. 2020 Apr;47(4):632. doi: 10.3899/jrheum.190538.PMID: 32238544.
38. Li AS, Tang PH, **Do DV**. Serous Macular Detachment in Probable Vogt-Koyanagi-Harada Syndrome. *JAMA Ophthalmol*. 2020 May 1;138(5):e191981. doi: 10.1001/jamaophthalmol.2019.1981. Epub 2020 May 14.PMID: 32407448.
39. Hassan M, Chakravarthy AD, Subramaniam M, Chundi P, Sadiq MA, Halim MS, Afridi R, Tran ANT, Sepah YJ, **Do DV**. Correction of perceived visual distortions using a software application and correlation to age-related macular degeneration. *Ther Adv Ophthalmol*. 2020 May 18;12:2515841420917783. doi: 10.1177/2515841420917783. eCollection 2020 Jan-Dec.PMID: 32524073.
40. Li AS, Nguyen HV, **Do DV**. Migration of a Fluocinolone Acetonide Intravitreal Implant in the Anterior Chamber. *JAMA Ophthalmol*. 2020 Oct 1;138(10):e201388. doi: 10.1001/jamaophthalmol.2020.1388. Epub 2020 Oct 8.
41. Azad AD, Chandramohan A, Li AS, Rosenblatt TR, Reeves MR, Veerappan-Pasricha M, Ludwig CA, Nguyen A, Wings KM, Wang SY, Pan CK, Moss HE, **Do DV**, Fountain TR, Kessler AL. Representation of Women in Ophthalmology Subspecialty Societies over 20 Years. *Ophthalmology*. 2022 May;129(5):587-590. doi: 10.1016/j.ophtha.2021.12.011. Epub 2021 Dec 24.PMID: 34958831
42. Moujahad AA, Vader D, **Do, DV**. Racial Differences in Anti-Vascular Endothelial Growth Factor Intravitreal Injections Among Commercially Insured Beneficiaries. *Ophthalmic Surg Lasers Imaging Retina*. 2021 Apr;52(4):208-217. doi: 10.3928/23258160-20210330-05. Epub 2021 Apr 1.
43. Lin CC, Li AS, Ma H, Lin X, Olivares M, Haubrich A, Sanislo S, **Do DV**. Successful interventions to improve efficiency and reduce patient visit duration in a retina practice. *Retina*. 2021 Mar 18. doi: 10.1097/IAE.0000000000003169. Online ahead of print.PMID: 33758134
44. Serous retinal detachment as a presenting sign of acute lymphoblastic leukemia: a case report and literature review. Veerappan Pasricha M, Callaway NF, Nguyen QD, **Do DV**. *Am J Ophthalmol Case Rep*. 2021 Jun 22;23:101142. doi: 10.1016/j.ajoc.2021.101142. eCollection 2021 Sep.

45. **Do DV**, Moini H, Wykoff CC. [Frequency and timing of antivasular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context.](#) *BMJ Open Ophthalmol.* 2022 Aug;7(1):e000983. doi: 10.1136/bmjophth-2022-000983.PMID: 36161828

46. Li AS, Korot E, Mishra K, Perloth A, **Do DV**. Wide-Field Swept-Source Optical Coherence Tomography of Optic Disc Pit Maculopathy Demonstrates Connection Between Vitreous and Subretinal Fluid. *Ophthalmic Surg Lasers Imaging Retina.* 2022 Oct;53(10):579-581. doi: 10.3928/23258160-20220819-01. Epub 2022 Oct 1.PMID: 36239681

47. **Do DV**, Gordon C, Suñer IJ, Reed K, Moini H, Gibson A, Du W, Shah CP. [Proliferative Diabetic Retinopathy Events in Patients With Diabetic Macular Edema: Post Hoc Analysis of VISTA and VIVID Trials.](#) *J Vitreoretin Dis.* 2022 Jun 4;6(4):295-301. doi: 10.1177/24741264221093914. eCollection 2022 Jul-Aug.PMID: 37007930

48. **Do DV**, Han G, Abariga SA, Sleilati G, Vedula SS, Hawkins BS. [Blood pressure control for diabetic retinopathy.](#) *Cochrane Database Syst Rev.* 2023 Mar 28;3(3):CD006127. doi: 10.1002/14651858.CD006127.pub3.PMID: 36975019 Review.

49. Rofail D, Sherman S, Hartford C, Levine A, Baldasaro J, Marquis P, Rao R, **Do DV**. [Development and Preliminary Validation of an Instrument to Measure Symptoms and Impacts in Patients with Proliferative Diabetic Retinopathy.](#) *Adv Ther.* 2023 Apr;40(4):1773-1786. doi: 10.1007/s12325-023-02447-8. Epub 2023 Feb 27.PMID: 36848017

50. Sherman SA, Rofail D, Levine A, Hartford CR, Baldasaro J, Marquis P, Rao R, **Do DV**. [The Patient Experience with Diabetic Retinopathy: Qualitative Analysis of Patients with Proliferative Diabetic Retinopathy.](#) *Ophthalmol Ther.* 2023 Feb;12(1):431-446. doi: 10.1007/s40123-022-00614-8. Epub 2022 Dec 3.PMID: 36460939

51. **Do DV**, Silva FQ, Du W, Reed K, Berliner AJ, Moini H. [Consistency of Treatment Effect with Aflibercept by Baseline Factors in PANORAMA.](#) *Ophthalmol Retina.* 2023 Jul;7(7):645-648. doi: 10.1016/j.oret.2023.03.005. Epub 2023 Mar 17.PMID: 36934879 No abstract available.

Review and other types of first or last author peer-review articles (Total: 18; Total at Stanford: 9)

1. Kaiser PK, **Do DV**. Ranibizumab for the treatment of neovascular AMD. *Int J Clin Pract* 2007;61:501-509.

2. **Do DV**, Hawkins B, Gichuhi S, Vedula SS. Surgery for post-vitrectomy cataract. *Cochrane Database Syst Rev.* 2008 Jul 16;(3):CD006366. Review

3. Khare GD, Symons RC, **Do DV**. Common ophthalmic emergencies. *Int J Clin Pract.* 2008 Nov;62(11):1776-84.

4. Csaky K, **Do DV**. Safety implications of vascular endothelial growth factor blockade for subjects receiving intravitreal anti-vascular endothelial growth factor therapies. *Am J Ophthalmol*. 2009 Nov;148(5):647-56.
5. **Do DV**. Detection of new-onset choroidal neovascularization. *Curr Opin Ophthalmol*. 2013 May;24(3):244-7.
6. Implications Of The Comparisons Of Age-Related Macular Degeneration Treatments Trials On Clinical Practice: What Have We Learned?
Do DV. *Ophthalmology*. 2013 May;120(5 Suppl):S8-10. Doi: 10.1016/J.Ophtha.2013.01.058.
7. Surgery for post-vitrectomy cataract.
Do DV, Gichuhi S, Vedula SS, Hawkins BS.
Cochrane Database Syst Rev. 2013 Dec 19;12:
8. Hassan M, Agarwal A, Afridi R, daSilva MJ, Karaca I, Sadiq MA, Nguyen QD, **Do DV**. The Role of Optical Coherence Tomography Angiography in the Management of Uveitis. *Int Ophthalmol Clin*. 2016 Fall;56(4):1-24.
9. Rhoades W, Dickson D, Nguyen QD, **Do DV**. Management of macular edema due to central retinal vein occlusion - The role of aflibercept. *Taiwan J Ophthalmol*. 2017 Apr-Jun;7(2):70-76. doi: 10.4103/tjo.tjo_9_17. Review.
10. **Do DV**, Gichuhi S, Vedula SS, Hawkins BS. Surgery for postvitrectomy cataract. *Cochrane Database Syst Rev*. 2018 Jan 10;1:CD006366. doi: 10.1002/14651858.CD006366.pub4.
11. Tang PH, Hariprasad SM, **Do DV**. Rethinking Management Strategies for Proliferative Diabetic Retinopathy. *Ophthalmic Surg Lasers Imaging Retina*. 2018 Apr 1;49(4):224-227. doi: 10.3928/23258160-20180329-01.
12. Csaky KG, Patel PJ, Sepah YJ, Birch DG, **Do DV**. Microperimetry for geographic atrophy secondary to age-related macular degeneration. *Surv Ophthalmol*. 2019 May-Jun;64(3):353-364.
13. Hassan M, Karkhur S, Bae JH, Halim MS, Ormaechea MS, Onghanseng N, Nguyen NV, Afridi R, Sepah YJ, **Do DV**. New therapies in development for the management of non-infectious uveitis: A review. *Clin Exp Ophthalmol*. 2019 Apr;47(3):396-417. doi: 10.1111/ceo.13511.PMID: 30938012.
14. Karkhur S, Hasanreisoglu M, Vigil E, Halim MS, Hassan M, Plaza C, Nguyen NV, Afridi R, Tran AT, **Do DV**. Interleukin-6 inhibition in the management of non-infectious uveitis and beyond. *J Ophthalmic Inflamm Infect*. 2019 Sep 16;9(1):17. doi: 10.1186/s12348-019-0182-y.PMID: 31523783.

15. Kuppermann BD, Bernstein P, Mones J, **Do DV**. ISOPT Clinical Hot Topic Panel Discussion on Medical Treatment of RETINAL Diseases. *J Ocul Pharmacol Ther.* 2019 Oct;35(8):424-432. doi: 10.1089/jop.2019.0073.PMID: 31596664.
16. Ormaechea MS, Hassan M, Onghanseng N, Park JH, Mahajan S, Al-Kirwi KY, Uludag G, Halim MS, Schlaen A, Sepah YJ, **Do DV**. Safety of systemic therapy for noninfectious uveitis. *Expert Opin Drug Saf.* 2019 Dec;18(12):1219-1235. doi: 10.1080/14740338.2019.1692810.PMID: 31801415.
17. Ludwig CA, Shields RA, **Do DV**. Traumatic chorioretinitis sclopetaria: Risk factors, management, and prognosis. *Am J Ophthalmol Case Rep.* 2019 Feb 16;14:39-46.
18. Nguyen QD, Das A, **Do DV**. Brolucizumab: Evolution through Preclinical and Clinical Studies and the Implications for the Management of Neovascular Age-Related Macular Degeneration. *Ophthalmology.* 2020 Jul;127(7):963-976. doi: 10.1016/j.ophtha.2019.12.031. Epub 2020 Jan 17.PMID: 32107066.

Middle author peer-review journal articles (Total: 95; Total at Stanford: 31)

1. Jun AS, Liu SH, Koo EH, **Do DV**, Stark WJ, Gottsch JD. "Microarray Analysis of Gene Expression in Human Donor Corneas." *Archives of Ophthalmology* 2001;119:1629-1634. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
2. Jun AS, Broman KW, **Do DV**, Akpek EK, Stark WJ, Gottsch JD. "Endothelial Dystrophy, Iris Hypoplasia, Congenital Cataract, and Stromal Thinning Syndrome (EDICT) Maps to Chromosome 15q22.1-q25.3" *American Journal of Ophthalmology* 2002;134(2):172-176. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
3. Akpek EK, Thorne JE, Qazi FA, **Do DV**, Jabs DA. "Evaluation of patients with scleritis for systemic disease." *Ophthalmology* 2004;111(3):501-506. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
4. Nguyen QD, Shah S, Tattipinar S, **Do DV**, Anden EV, Campochiaro PA. "Bevacizumab suppresses choroidal neovascularization caused by pathologic myopia." *British Journal of Ophthalmology* 2005;89(10):1368-70. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
5. Ober MD, Yannuzzi LA, **Do DV**, Spaide RF, Bressler NM, Jampol LM, Angellili A, Eandi CM, Lyon AT. "Photodynamic therapy for focal retinal pigment epithelial leaks secondary to central serous chorioretinopathy." *Ophthalmology* 2005;112:2088-2094. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
6. Nguyen QD, Tattipinar S, Shah SM, Haller JA, Quinlan E, Sung JU, Zimmer-Galler I, **Do DV**, Campochiaro PA. Vascular endothelial growth factor is a critical stimulus for diabetic macular edema. *American Journal of Ophthalmology* 2006;142:961-969. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

7. Gerstenblith AT, Thorne JE, Sobrin L, **Do DV**, Shah SM, Foster CS, Jabs DA, Nguyen QD. Punctate inner choroidopathy: a survey analysis of 77 persons. *Ophthalmology*. 2007;114(6):1201-4. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
8. Nguyen QD, Shah SM, Hafiz G, **Do DV**, Haller JA, Pili R, Zimmer-Galler I, Janjua K, Symons RCA, Campochiaro PA. Intravenous bevacizumab causes regression of choroidal neovascularization secondary to diseases other than age-related macular degeneration. *American Journal of Ophthalmology* 2008; 145(2): 257-266. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
9. Campochiaro PA, Hafiz G, Shah SM, Nguyen QD, Ying H, **Do DV**, Quinlan E, Zimmer-Galler I, Haller JA, Solomon SD, Sung JU, Hadi Y, Janjua KA, Jawed N, Choy DF, Arron JR. Ranibizumab for macular edema due to Retinal Vein Occlusions; Implication of VEGF as a Critical Stimulator. *Molecular Therapy* 2008; Apr;16(4):791-9 *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
10. Sodhi A, Leung LS, **Do DV**, Gower EW, Schein OD, Handa JT. Recent trends in the management of rhegmatogenous retinal detachment. *Surv Ophthalmol*. 2008 Jan-Feb;53(1):50-67. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
11. Nguyen-Khoa BA, Goerhing EL Jr, Wether W, Gower EW, **Do DV**, Jones, JK. Hospitalized cardiovascular diseases in age-related macular degeneration. *Arch Ophthalmol*. 2008;126:1280-1286. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
12. Khurana RN, **Do DV**, Nguyen QD. Anti-VEGF therapeutic approaches for diabetic macular edema. *Int Ophthalmol Clin*. 2009 Spring;49(2):109-19. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
13. Nguyen QD, Shah SM, Browning DJ, Hudson H, Sonkin P, Hariprasad SM, Kaiser P, Slakter JS, Haller J, **Do DV**, Mieler WF, Chu K, Yang K, Ingerman A, Vitti RL, Berliner AJ, Cedarbaum JM, Campochiaro PA. A Phase I Study of Intravitreal Vascular Endothelial Growth Factor Trap-Eye in Patients with Neovascular Age-Related Macular Degeneration. *Ophthalmology*. 2009 Nov;116(11):2141-8.e1 *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
14. Campochiaro PA, Choy DF, **Do DV**, Hafiz G, Shah SM, Nguyen QD, Rubio R, Arron JR. Monitoring Ocular Drug Therapy by Analysis of Aqueous Samples. *Ophthalmology*. 2009 Nov;116(11):2158-64. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
15. Nguyen QD, Shah SM, Heier JS, **Do DV**, Lim J, Boyer D, Abraham P, Campochiaro PA; READ-2 Study Group. Primary End Point (Six Months) Results of the Ranibizumab for Edema of the mAcula in Diabetes (READ-2) Study. *Ophthalmology*. 2009 Nov;116(11):2175-81.e1. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

16. Kashani AH, Zimmer-Galler IE, Shah SM, Dustin L, **Do DV**, Elliott D, Haller JA, Nguyen QD. Retinal thickness analysis by race, gender, and age using Stratus OCT. *Am J Ophthalmol.* 2010 Mar;149(3):496-502.e1. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

17. Shah SM, Nguyen QD, Mir HS, Polito A, Hafiz G, Tatlipinar S, **Do DV**, Vitale S, Haller JA. A randomized, double-masked controlled clinical trial of Sandostatin long-acting release depot in patients with postsurgical cystoid macular edema. *Retina.* 2010 Jan;30(1):160-6. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

18. Campochiaro PA, Shah SM, Hafiz G, Heier JS, Lit ES, Zimmer-Galler I, Channa R, Nguyen QD, Syed B, **Do DV**, Lu L, Monk J, Cooke JP, Kengatharan MK, Hsu HH. Topical mecamlamine for diabetic macular edema. *Am J Ophthalmol.* 2010 May;149(5):839-51.e1. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

19. Kaiser PK, Symons RC, Shah SM, Quinlan EJ, Tabandeh H, **Do DV**, Reisen G, Lockridge JA, Short B, Guercioli R, Nguyen QD; Sirna-027 Study Investigators. RNAi-based treatment for neovascular age-related macular degeneration by Sirna-027. *Am J Ophthalmol.* 2010 Jul;150(1):33-39. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

20. Campochiaro PA, Hafiz G, Channa R, Shah SM, Nguyen QD, Ying H, **Do DV**, Zimmer-Galler I, Solomon SD, Sung JU, Syed B. Antagonism of Vascular Endothelial Growth Factor for Macular Edema Caused by Retinal Vein Occlusions: Two-Year Outcomes. *Ophthalmology.* 2010 Jul 12. *Role in study: participated in design, interpretation of results, writing and review of manuscript. I was also a co-investigator.*

21. Wang J, Ibrahim M, Turkcuoglu P, Hatef E, Khwaja A, Channa R, **Do DV**, Nguyen QD. Intercellular adhesion molecule inhibitors as potential therapy for refractory uveitic macular edema. *Ocul Immunol Inflamm.* 2010 Oct;18(5):395-8. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

22. Chang MA, **Do DV**, Bressler SB, Cassard SD, Gower EW, Bressler NM. Prospective one-year study of ranibizumab for predominantly hemorrhagic choroidal neovascular lesions in age-related macular degeneration. *Retina.* 2010 Sep;30(8):1171-6. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

23. Nguyen QD, Shah SM, Khwaja AA, Channa R, Hatef E, **Do DV**, Boyer D, Heier JS, Abraham P, Thach AB, Lit ES, Foster BS, Kruger E, Dugel P, Chang T, Das A, Ciulla TA, Pollack JS, Lim JI, Eliot D, Campochiaro PA; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the macula in diabetes (READ-2) study. *Ophthalmology.* 2010 Nov;117(11):2146-51. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

24. Ramulu PY, **Do DV**, Corcoran KJ, Corcoran SL, Robin AL. Use of retinal procedures in medicare beneficiaries from 1997 to 2007. *Arch Ophthalmol.* 2010 Oct;128(10):1335-40. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

25. Werther W, Chu L, Holekamp N, **Do DV**, Rubio RG. Myocardial infarction and cerebrovascular accident in patients with retinal vein occlusion. Arch Ophthalmol. 2011;129(3):326-331. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

26. Hatf E, Turkcuoglu P, Ibrahim M, Sepah Y, Shulman M, Heo J, Lee JH, Channa R, Khwaja A, Rentiya Z, Shah SM, **Do DV**, Nguyen QD. Importance of proper diagnosis for management: multifocal choroiditis mimicking ocular histoplasmosis syndrome. J Ophthalmic Inflamm Infect. 2011;1(2):55-63. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

27. Turkcuoglu P, Chang PY, Rentiya ZS, Channa R, Ibrahim M, Hatf E, Sophie R, Sadaka A, Wang J, Sepah YJ, **Do DV**, Foster CS, Nguyen QD. Mycophenolate mofetil and fundus autofluorescence in the management of recurrent punctate inner choroidopathy. Ocul Immunol Inflamm. 2011;19(4):286-292. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

28. Ibrahim MA, Sepah YJ, Symons RC, Channa R, Hatf E, Khwaja A, Bittencourt M, Heo J, **Do DV**, Nguyen QD. Spectral- and time-domain optical coherence tomography measurements of macular thickness in normal eyes and in eyes with diabetic macular edema. Eye (Lond). 2012 Mar;26(3):454-62. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

29. Sepah YJ, Hatf E, Colantuoni E, Wang J, Shulman M, Adhi FI, Akhtar A, Ibrahim M, Khwaja A, Channa R, Sophie R, Bittencourt M, Heo J, **Do DV**, Nguyen QD. Macular sensitivity and fixation patterns in normal eyes and eyes with uveitis with and without macular edema. J Ophthalmic Inflamm Infect. 2021 Jun;2(2):65-73. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

30. Channa R, Ibrahim M, Sepah Y, Turkcuoglu P, Lee JH, Khwaja A, Hatf E, Bittencourt M, Heo J, **Do DV**, Nguyen QD. Characterization of macular lesions in punctate inner choroidopathy with spectral domain optical coherence tomography. J Ophthalmic Inflamm Infect. 2012 Sep;2(3):113-20. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

31. Liu TY, Ibrahim M, Bittencourt M, Sepah YJ, **Do DV**, Nguyen QD. Retinal optical coherence tomography manifestations of intraocular lymphoma. J Ophthalmic Inflamm Infect. 2012 Dec;2(4):215-8. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

32. Yohannan J, Channa R, Dibernardo CW, Zimmer-Galler IE, Ibrahim M, Sepah YJ, Bittencourt M, **Do DV**, Nguyen QD. Sclerochoroidal calcifications imaged using enhanced depth imaging optical coherence tomography. Ocul Immunol Inflamm. 2012 Jun;20(3):190-2. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

33. Nguyen-Khoa BA, Goehring EL Jr, Werther W, Fung AE, **Do DV**, Apte RS, Jones JK. Hospitalized cardiovascular events in patients with diabetic macular edema. BMC Ophthalmol. 2012 May 30;12(1):11. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

34. Nguyen QD, Campochiaro PA, Shah SM, Browning DJ, Hudson HL, Sonkin PL, Hariprasad SM, Kaiser PK, Slakter J, Haller JA, **Do DV**, Mieler W, Chu K, Ingerman A, Vitti R, Berliner AJ, Cedarbaum J; Clear-It 1 Investigators. Evaluation of very high- and very low-dose intravitreal aflibercept in patients with neovascular age-related macular degeneration. *J Ocul Pharmacol Ther.* 2012 Dec;28(6):581-8. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
35. Heo J, Sepah YJ, Yohannan J, Renner M, Akhtar A, Gregory A, Shulman M, **Do DV**, Nguyen QD. The role of biologic agents in the management of non-infectious uveitis. *Expert Opin Biol Ther.* 2012 Aug;12(8):995-1008. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
36. Hatef E, Khwaja A, Rentiya Z, Ibrahim M, Shulman M, Turkcuoglu P, Sepah Y, Wang J, Channa R, Bittencourt M, Akhtar A, Heo J, **Do DV**, Nguyen QD. Comparison of time domain and spectral domain optical coherence tomography in measurement of macular thickness in macular edema secondary to diabetic retinopathy and retinal vein occlusion. *J Ophthalmol.* 2012;2012:354783. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
- 37 Campbell JP, Leder HA, Sepah YJ, Gan T, Dunn JP, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, **Do DV**, Nguyen QD. Wide-field retinal imaging in the management of noninfectious posterior uveitis. *Am J Ophthalmol.* 2012 Nov;154(5):908-911. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
38. Ibrahim MA, **Do DV**, Sepah YJ, Shah SM, Van Anden E, Hafiz G, Donahue JK, Rivers R, Balkissoon J, Handa JT, Campochiaro PA, Nguyen QD. Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin A-4 phosphate. *BMC Pharmacol Toxicol.* 2013 Jan 14;14:7. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
39. Tauqir MZ, Shulman M, Bittencourt M, Sepah YJ, Ibrahim M, **Do DV**, Nguyen QD, Foster CS, Vora RA, Albin TA. Diagnostic and therapeutic challenges. *Retina.* 2013 Apr;33(4):883-8. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
40. Yohannan J, Bittencourt M, Sepah YJ, Hatef E, Sophie R, Moradi A, Liu H, Ibrahim M, **Do DV**, Coulantuoni E, Nguyen QD. Association of Retinal Sensitivity to Integrity of Photoreceptor Inner/Outer Segment Junction in Patients with Diabetic Macular Edema. *Ophthalmology.* 2013 June;120(6):1254-61. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
41. Leder HA, Campbell JP, Sepah YJ, Gan T, Dunn JP, Hatef E, Cho B, Ibrahim M, Bittencourt M, Channa R, **Do DV**, Nguyen QD. Ultra-wide-field retinal imaging in the management of non-infectious retinal vasculitis. *J Ophthalmic Inflamm Infect.* 2013 Feb 11;3(1):30. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

42. Nguyen QD, **Do DV**, Haller JA, Heier JS, Kaiser PK. Putting Theories And Results Into Practice: Managing Cases. *Ophthalmology*. 2013 May;120(5 Suppl):S16-22. Doi: 10.1016/J.Ophtha.2013.01.060. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
43. Jang HS, Sepah YJ, Sophie R, Bittencourt MG, Ferraz D, Hanout M, Liu H, **Do DV**, Nguyen QD. Longitudinal spectral domain optical coherence tomography changes in eyes with intraocular lymphoma. *J Ophthalmic Inflamm Infect*. 2013 Sep 8;3(1):59. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
44. Sophie R, Hafiz G, Scott AW, Zimmer-Galler I, Nguyen QD, Ying H, **Do DV**, Solomon S, Sodhi A, Gehlbach P, Duh E, Baranano D, Campochiaro PA. Long-term outcomes in ranibizumab-treated patients with retinal vein occlusion; the role of progression of retinal nonperfusion. *Am J Ophthalmol*. 2013 Oct;156(4):693-705. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
45. Shulman M, Sepah YJ, Chang S, Abrams GW, **Do DV**, Nguyen QD. . Management of retained subretinal perfluorocarbon liquid. *Ophthalmic Surg Lasers Imaging Retina*. 2013 Nov 1;44(6):577-83. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
46. Channa R, Sophie R, Khwaja AA, **Do DV**, Hafiz G, Nguyen QD, Campochiaro PA; READ-2 Study Group. Factors affecting visual outcomes in patients with diabetic macular edema treated with ranibizumab. *Eye (Lond)*. 2014 Mar;28(3):269-78. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
47. Driving habits in older patients with central vision loss. Sengupta S, van Landingham SW, Solomon SD, **Do DV**, Friedman DS, Ramulu PY. *Ophthalmology*. 2014 Mar;121(3):727-32. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
48. Hanout M, Ferraz D, Ansari M, Maqsood N, Kherani S, Sepah YJ, Rajagopalan N, Ibrahim M, **Do DV**, Nguyen QD. Therapies for neovascular age-related macular degeneration: current approaches and pharmacologic agents in development. *Biomed Res Int*. 2013;2013:830-837. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
49. Moradi A, Sepah YJ, Sadiq MA, Nasir H, Kherani S, Sophie R, **Do DV**, Nguyen QD. *World J Diabetes*. Vascular endothelial growth factor trap-eye (Aflibercept) for the management of diabetic macular edema. 2013 Dec 15;4(6):303-9. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
50. Liu MM, Wolfson Y, Bressler SB, **Do DV**, Ying HS, Bressler NM. Comparison of time- and spectral-domain optical coherence tomography in management of diabetic macular edema. *Invest Ophthalmol Vis Sci*. 2014 Mar 6;55(3):1370-7. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*
51. Moradi A, Sepah YJ, Ibrahim MA, Sophie R, Moazes C, Bittencourt MG, Annam RE, Hanout M, Liu H, Ferraz D, **Do DV**, Nguyen QD. Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab. *Eye (Lond)*. 2014 Nov; 28(11)1315-1320. *Role in study: participated in design, interpretation of*

results, writing and review of manuscript.

52. Hatef E, Hanout M, Moradi A, Colantuoni E, Bittencourt M, Liu H, Sepah YJ, Ibrahim M, **Do DV**, Guyton DL, Nguyen QD. Longitudinal comparison of visual acuity as measured by the ETDRS chart and by the potential acuity meter in eyes with macular edema, and its relationship with retinal thickness and sensitivity. *Eye (Lond)*. 2014 Oct;28(10):1239-1245. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

53. Wilson FA, Wang Y, Stimpson JP, Sikora A, **Do DV**, Britigan DH. Disparities in Visual Impairment by Immigrant Status in the United States. *American Journal Ophthalmology Am J Ophthalmol* 2014 Oct;158(4):800-807. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

54. Korobelnik JF, **Do DV**, Schmidt-Erfurth U, Boyer DS, Holz FG, Heier JS, Midena E, Kaiser PK, Terasaki H, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Yancopoulos GD, Stahl N, Vitti R, Berliner AJ, Zeitz O, Metz C, Brown DM. Intravitreal Aflibercept for Diabetic Macular Edema. *Ophthalmology*. 2014 Nov;121(11):2247-2254. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

55. Wilson FA, Wang Y, Stimpson JP, Kessler AS, **Do DV**, Britigan DH. Disparities in visual impairment by immigrant status in the United States. *Am J Ophthalmol*. 2014 Oct;158(4):800-807. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

56. Regillo CD, Callanan DG, **Do DV**, Fine HF, Holekamp NM, Kuppermann BD, Singer MA, Singh RP. Use of Corticosteroids in the Treatment of Patients with Diabetic Macular Edema Who Have a Suboptimal Response to Anti-VEGF: Recommendations of an Expert Panel. *Ophthalmic Surg Lasers Imaging Retina*. 2017 Apr 1;48(4):291-301. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

57. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, **Do DV**, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metz C, Holz FG. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. *Ophthalmology*. 2016 Nov;123(11):2376-2385. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

58. Heo JW, Cho BJ, Goldstein DA, Sepah YJ, **Do DV**, Nguyen QD. Fluocinolone acetonide implant for Vogt-Koyanagi-Harada Disease: Three-Year Outcomes of Efficacy and Safety. *Retina*. 2016 Nov;36(11):2124-2131. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

59. Nguyen QD, Sadiq MA, Soliman MK, Agarwal A, **Do DV**, Sepah YJ. The Effect of Different Dosing Schedules of Intravitreal Sirolimus, a Mammalian Target of Rapamycin (mTOR) Inhibitor, in the Treatment of Non-Infectious Uveitis (An American Ophthalmological Society Thesis). *Trans Am Ophthalmol Soc*. 2016 Aug;114:T3. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

60. Sarwar S, Hanout M, Sadiq MA, Soliman MK, Agarwal A, **Do DV**, Nguyen QD, Sepah

YJ. Retinal Vessel Caliber Measurement Using MultiColor and Infrared Confocal Scanning Laser Ophthalmoscopy Fundus Images. *Int Ophthalmol Clin.* 2016 Fall;56(4):67-83. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

61. Kozak I, Barteselli G, Sepah YJ, Sadiq MA, High R, **Do DV**, Nguyen QD. Correlation of Vitreomacular Traction with Foveal Thickness, Subfoveal Choroidal Thickness, and Vitreomacular/Foveal Angle. *Curr Eye Res.* 2017 Feb;42(2):297-301. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

62. Ballard DH, **Do DV**, Laborde JJ, de Gregorio MA, Shi R, D'Agostino HB. Observations on failed retrieval of optional inferior vena cava filters. *Clin Imaging.* 2016 Sep-Oct;40(5):931-5. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

63. Campochiaro PA, Hafiz G, Mir TA, Scott AW, Solomon S, Zimmer-Galler I, Sodhi A, Duh E, Ying HS, Wenick AS, Shah SM, **Do DV**, Nguyen QD, Kherani S, Sophie R. Scatter photocoagulation does not reduce macular edema or treatment burden in patients with retinal vein occlusion: the RELATE trial. *Ophthalmology.* 2015 Jul;122(7):1426-37. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

64. Agarwal A, Soliman M, Sarwar S, Sadiq MA, **Do DV**, Nguyen QD, Sepah YJ. Spectral-domain optical coherence tomography evaluation of retinal structures in patients with Susacs syndrome. *Retina Cases Brief Rep.* 2017 Spring;11(2):123-125. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

65. Kitchens JW, **Do DV**, Boyer DS, Thompson D, Gibson A, Saroj N, Vitti R, Berliner AJ, Kaiser PK. Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials. *Ophthalmology.* 2016 Jul;123(7):1511-20. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

66. Soliman MK, Sadiq MA, Agarwal A, Sarwar S, Hassan M, Hanout M, Graf F, High R, **Do DV**, Nguyen QD, Sepah YJ. High-Resolution Imaging of Parafoveal Cones in Different Stages of Diabetic Retinopathy Using Adaptive Optics Fundus Camera. *PLoS One.* 2016 Apr 8;11(4):e0152788. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

67. Hassan M, Afridi R, Sadiq MA, Soliman MK, Agarwal A, Sepah YJ, **Do DV**, Nguyen QD. The role of Aflibercept in the management of age-related macular degeneration. *Expert Opin Biol Ther.* 2016;16(5):699-709. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

68. Demirel S, Argo C, Agarwal A, Parriott J, Sepah YJ, **Do DV**, Nguyen QD. Updates on the Clinical Trials in Diabetic Macular Edema. *Middle East Afr J Ophthalmol.* 2016 Jan-Mar;23(1):3-12. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

69. Sadiq MA, Hassan M, Afridi R, Halim MS, **Do DV**, Sepah YJ, Nguyen QD, STOP-UVEITIS Investigators. Posterior segment inflammatory outcomes assessed using fluorescein angiography in the STOP-UVEITIS study. *Int J Retina Vitreous.* 2020 Oct 6;6:47. *Role in study: participated in design, interpretation of results, writing and review of*

manuscript.

70. Regillo CD, Callanan DG, **Do DV**, Fine HF, Holekamp NM, Kuppermann BD, Singer MA, Singh RP. Use of Corticosteroids in the treatment of patients with diabetic macular edema who have a suboptimal response to anti-VEGF: recommendations of an expert panel. *Ophthalmic Surg Lasers Imaging Retina*. 2017 Apr 1;48(4):291-301. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

71. Sepah YJ, Sadiq MA, Chu DS, Dacey M, Gallemore R, Dayani P, Hanout M, Hassan M, Afridi R, Agarwal A, Halim MS, **Do DV**, Nguyen QD. Primary (Month-6) Outcomes of the STOP-Uveitis Study: Evaluating the Safety, Tolerability, and Efficacy of Tocilizumab in Patients with Non-Infectious Uveitis. *Am J Ophthalmol*. 2017 Sep 5. pii: S0002-9394(17)30373-2. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

72. Saldanha IJ, Lindsley K, **Do DV**, Chuck RS, Meyerle C, Jones LS, Coleman AL, Jampel HD, Dickersin K, Virgili G. Comparison of Clinical Trial and Systematic Review Outcomes for the 4 Most Prevalent Eye Diseases. *JAMA Ophthalmol*. 2017 Sep 1;135(9):933-940. doi: 10.1001/jamaophthalmol.2017.2583. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

73. Heier JS, Korobelnik JF, Brown DM, Schmidt-Erfurth U, **Do DV**, Midena E, Boyer DS, Terasaki H, Kaiser PK, Marcus DM, Nguyen QD, Jaffe GJ, Slakter JS, Simader C, Soo Y, Schmelter T, Vitti R, Berliner AJ, Zeitz O, Metz C, Holz FG. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. *Ophthalmology*. 2016 Nov;123(11):2376-2385. doi: 10.1016/j.ophtha.2016.07.032. Epub 2016 Sep 17. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

74. Agarwal A, Karkhur S, Aggarwal K, Invernizzi A, Singh R, Dogra MR, Gupta V, Gupta A, **Do DV**, Nguyen QD. Epidemiology and clinical features of inflammatory retinal vascular occlusions: pooled data from two tertiary-referral institutions. *Clin Exp Ophthalmol*. 2018 Jan;46(1):62-74. doi: 10.1111/ceo.12997. Epub 2017 Jun 20. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

75. Agarwal A, Afridi R, Agrawal R, **Do DV**, Gupta V, Nguyen QD. Multimodal Imaging in Retinal Vasculitis. *Ocul Immunol Inflamm*. 2017 Jun;25(3):424-433. doi: 10.1080/09273948.2017.1319494. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

76. Hassan M, Sadiq MA, Halim MS, Afridi R, Soliman MK, Sarwar S, Agarwal A, **Do DV**, Nguyen QD, Sepah YJ. Evaluation of macular and peripapillary vessel flow density in eyes with no known pathology using optical coherence tomography angiography. *Int J Retina Vitreous*. 2017 Jul 31;3:27. doi: 10.1186/s40942-017-0080-0. eCollection 2017. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

77. Nguyen QD, Heier JS, **Do DV**, Miando AC, Pandey NB, Sheng H, Heah T. The Tie2 signaling pathway in retinal vascular diseases: a novel therapeutic target in the eye. *Int J Retina Vitreous* 2020 Oct13;6:48. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

78. Halim MS, Onghanseng N, Park JH, Yilmaz M, Segawa A, Ertop M, Hassan M, Tran AN, Aktas Z, Ozdek S, Gurelik G, **Do DV**, Sepah YJ, Nguyen QD, Hasanreisoglu M. Effect of fundus fluorescein angiography on semiautomated aqueous flare measurements. *Ocul Immunol Inflamm.* 2020 Sep 23;1-4. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

79. Azad AD, Chandramohan A, Li AS, Rosenblatt TR, Reeves MG, Veerappan M, Ludwig CA, Nguyen A, Wings K, Wang S, Pan C, Moss H, **Do DV**, Fountain T, Kossler AL. Representation of women within ophthalmology subspecialty societies: a 20-year analysis. 2021 Accepted for publication in *Journal of VitreoRetinal Diseases*. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

80. Kaiser PK, Wykoff CC, Singh RP, Khanani AM, **Do DV**, Patel H, Patel N. Retina. Retinal fluid and thickness as measures of disease activity in neovascular age-related macular degeneration. *Retina* 2021 Aug 1;41(8):1579-1586. doi: 10.1097/IAE.0000000000003194. PMID: 33949342 *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

81. Halim MS, Afridi R, Hasanreisoglu M, Hassan M, Ibrahim-Ahmed M, **Do DV**, Sepah YJ; READ-3 Investigators. Differences in the characteristics of subjects achieving complete, partial or no resolution of macular edema in the READ-3 study. *Graefes Arch Clin Exp Ophthalmol.* 2021 Oct;259(10)2942-2948. *Role in study: participated in design, interpretation of results, writing and review of manuscript*

82. Azad AD, Chandramohan A, Li AS, Rosenblatt TR, Reeves MR, Veerappan-Pasricha M, Ludwig CA, Nguyen A, Wings KM, Wang SY, Pan CK, Moss HE, **Do DV**, Fountain TR, Kossler AL. Representation of women in ophthalmology subspecialty societies over 20 years. *Ophthalmology* 2021 Dec 24;S0161-6420. *Role in study: participated in design, interpretation of results, writing and review of manuscript.*

83. Halim MS, Hasanreisoglu M, Onghanseng N, Tran ANT, Hassan M, Yilmaz M, Segawa A, Gurelik G, Afridi R, Ormaechea MS, Uludag G, Kesim C, Nguyen NV, Bae JH, Park JH, **Do DV**, Ibrahim MA, Sepah YJ, Nguyen QD. Correlation of clinical aqueous flare grading to semi-automated flare measurements using laser flare photometry. *Ocul Immunol Inflamm.* 2022 Jan 26;1-7.

84. Hassan M, Sadiq MA, Ormaechea MS, Uludağ G, Halim MS, Afridi R, **Do DV**, Sepah YJ, Nguyen QD. Utilisation of composite endpoint outcome to assess efficacy of tocilizumab for non-infectious uveitis in the STOP-Uveitis Study. *Br J Ophthalmol.* 2022 Apr 4;bjophthalmol-2021-320604. doi: 10.1136/bjophthalmol-2021-320604. Online ahead of print. PMID: 35379598

85. Uludag G, Hassan M, Matsumiya W, Pham BH, Chea S, Trong Tuong Than N, Doan HL, Akhavanrezayat A, Halim MS, **Do DV**, Nguyen QD. Efficacy and safety of intravitreal anti-VEGF therapy in diabetic retinopathy: what we have learned and what should we learn further? *Expert Opin Biol Ther.* 2022 Oct;22(10):1275-1291. doi: 10.1080/14712598.2022.2100694. Epub 2022 Jul 17. PMID: 35818801

86. Khan NC, Perera C, Dow ER, Chen KM, Mahajan VB, Mruthyunjaya P, **Do DV**, Leng T, Myung D. Predicting Systemic Health Features from Retinal Fundus Images Using Transfer-Learning-Based Artificial Intelligence Models. *Diagnostics (Basel)*. 2022 Jul 14;12(7):1714. doi: 10.3390/diagnostics12071714.PMID: 35885619

87. Ghoraba HH, **Do DV**, Nguyen QD. Port Delivery System With Ranibizumab: As Always - Risks Versus Benefits for the Recipients. *Ophthalmic Surg Lasers Imaging Retina*. 2022 Aug;53(8):416-417. doi: 10.3928/23258160-20220713-01. Epub 2022 Aug 1.PMID: 35951716

88. Hasanreisoglu M, Halim MS, Kesim C, Doan HL, Tran ANT, Nguyen W, Besalti Z, Lajevardi S, Hassan M, Akhavanrezayat A, Ahmed MI, **Do DV**, Sepah YJ, Nguyen QD. [Longitudinal Comparative Analysis of Semi-Automated Aqueous Flare Measurements with Clinical Grading and Visual Outcomes in Uveitic Eyes](#). *Ocul Immunol Inflamm*. 2022 Sep 28;1-6. doi: 10.1080/09273948.2022.2123365.

89. Dow ER, Khan NC, Chen KM, Mishra K, Perera C, Narala R, Basina M, Dang J, Kim M, Levine M, Phadke A, Tan M, Weng K, **Do DV**, Moshfeghi DM, Mahajan VB, Mruthyunjaya P, Leng T, Myung D. [AI-Human Hybrid Workflow Enhances Teleophthalmology for the Detection of Diabetic Retinopathy](#). *Ophthalmol Sci*. 2023 May 12;3(4):100330. doi: 10.1016/j.xops.2023.100330. eCollection 2023 Dec.PMID: 37449051

90. Al-Lozi A, Koo EB, Lambert SR, Levin MH, Velez FG, **Do DV**, Shue A.J [Anterior segment ischemia following strabismus surgery in a young adult using gender-affirming estrogen hormone therapy](#). *AAPOS*. 2023 Aug;27(4):233-236. doi: 10.1016/j.jaapos.2023.05.004. Epub 2023 Jun 23.PMID: 37355012

91. Matsumiya W, Karaca I, Pham BH, Akhavanrezayat A, Uludag G, Yasar C, Ghoraba H, Mobasserian A, Regenold J, Halim MS, Sepah YJ, **Do DV**, Chong V, Nguyen QD. Association of oral montelukast with reduced odds of developing exudative age-related macular degeneration. *Retina*. 2023 Jun 16. doi: 10.1097/IAE.0000000000003870. Online ahead of print.PMID: 37339446

92. Regenold J, Ghoraba H, Akhavanrezayat A, Ongpalakorn P, Bazojoo V, **Do DV**, Nguyen QD, Or C. [Birdshot chorioretinopathy in an HLA-A29 positive Asian patient](#). *Am J Ophthalmol Case Rep*. 2023 Jan 18;29:101802. doi: 10.1016/j.ajoc.2023.101802. eCollection 2023 Mar.PMID: 36741421

93. Khojasteh H, Riazi-Esfahani H, Mirghorbani M, Khalili Pour E, Mahmoudi A, Mahdizad Z, Akhavanrezayat A, Ghoraba H, **Do DV**, Nguyen QD. Cataract surgery in patients with retinitis pigmentosa: systematic review. *J Cataract Refract Surg*. 2023 Mar 1;49(3):312-320. doi: 10.1097/j.jcrs.0000000000001101. Epub 2022 Nov 21.PMID: 36730350

94. Khan NC, Perera C, Dow ER, Chen KM, Mahajan VB, Mruthyunjaya P, **Do DV**, Leng T, Myung D. Predicting Systemic Health Features from Retinal Fundus Images Using Transfer-Learning-Based Artificial Intelligence Models. *Diagnostics (Basel)*. 2022 Jul 14;12(7):1714. doi: 10.3390/diagnostics12071714.PMID: 35885619

95. Uludag G, Karaca I, Akhavanrezayat A, Yasar C, Matsumiya W, Pham BH, Halim MS, Trong Tuong Than N, Sepah YJ, **Do DV**, Nguyen QD. [Efficacy and Safety of Tocilizumab](#)

[in the Management of Non-Infectious Uveitis Failed with Conventional Immunomodulatory and Anti-TNF \$\alpha\$ Therapies.](#) Ocul Immunol Inflamm. 2022 Dec 21:1-7. doi: 10.1080/09273948.2022.2126374. Online ahead of print.PMID: 36542775

Book Chapters (24)

1. Nguyen QD, **Do DV**. Areas of fundus whitening: geographic whitening. Clinical Pathways in Retinal Diseases, ME Hartnett and S Steidl, Editors. Thieme Books Publishing, 2003:155-158.
2. **Do DV**, Bressler SB, Bressler NM. Pathologic myopia and choroidal neovascularization. Midena E, ed. Fondazione G.B. Beitti per lo Studio e la Ricerca in Oftalmologia - ONLUS Myopia and Related Diseases, 1st ed. New York: Ophthalmic Communications Society, Inc.; 2005:270-278.
3. **Do DV**, Garibaldi D, Carr R, Sunness J. Hereditary choroidal diseases. Retina, 4th Edition, SJ Ryan, Editor. Elsevier/Mosby Publishing; 2006:499-508.
4. **Do DV**, Haller JA. Coats' disease. Retina, 4th Edition, SJ Ryan, Editor. Elsevier/Mosby Publishing; 2006:1417-1424.
5. **Do DV**, Loewenstein A, Green WR, Haller JA. Vitreous, retinal, and choroidal biopsy. Retina, 4th Edition, SJ Ryan, Editor, Elsevier/Mosby Publishing; 2006:779-790.
6. Hawkins B, **Do DV**. Retina-related clinical trials: a resource bibliography. Retina, 4th Edition, SJ Ryan, Editor, Elsevier/Mosby Publishing; 2006:1557-1582.
7. **Do DV**, Loewenstein A, Haller JA. Transscleral diode laser retinopexy in the treatment of retinal detachment. Vitreoretinal Surgical Techniques, 2nd Edition, Peyman GA, Editor, Martin Dunitz Publishing; 2007:303-306.
8. **Do DV** and Haller JA. Coats disease and retinal telangiectasia. Ophthalmology, 3rd Edition. Yanoff and Duker, Editors. Elsevier Publishing; 2007: 631-635.
9. **Do DV** and Hawkins BS. Ocular histoplasmosis. Current Ocular Therapy, 6th edition, Roy and Fraunfelder, Editors, Elsevier Publishing 2008:61-62
10. Nguyen QD, **Do DV**. Uveitis associated with juvenile idiopathic arthritis. Current Ocular Therapy, 6th edition, Roy and Fraunfelder, Editors, Elsevier Publishing 2008:180-182.
11. **Do DV**, Nguyen QD, Haller JA. Retinal arterial macroaneurysms. Albert and Jakobiec's Principles and Practice of Ophthalmology, 3rd Edition, Albert D and Miller J, Editors, Elsevier Publishing 2008:1841-1848.
12. **Do DV** and Schachat AP. "Leukemias" in Albert and Jakobiec's Principles and Practice of Ophthalmology, 3rd Edition, Albert D and Miller J, Editors, Elsevier Publishing 2008:4949-4952.

13. Bressler SB, **Do DV**, Bressler NM. Age-related macular degeneration: drusen and geographic atrophy. Albert and Jakobiec's Principles and Practice of Ophthalmology, 3rd Edition, Albert D and Miller J, Editors, Elsevier Publishing 2008:1901-1916.
14. **Do DV**, Nguyen QD, Shah MS, Haller, JA. Ranibizumab for the Treatment of Diabetic Macular Edema. Retinal Vascular Disease, 1st Edition, Jousseaume, Gardner, Kirchhof, Ryan, Editors, Springer-Verlag Publishing 2007:125-130.
15. **Do DV**, Haller JA, Adamis A, Striata C, Nguyen QD, Shah MS, Jousseaume A. Anti-VEGF therapy as an emerging treatment for diabetic retinopathy. Diabetic Retinopathy, 1st edition. Duh, Editor. Humana Press, 2008:401-422.
16. **Do DV**, Haller JA. Treatment algorithm for diabetic macular edema. Diabetes and Ocular Disease: past, present, and future therapies. Scott, Flynn, Smiddy Editors, Oxford University Press 2010:251-264.
17. **Do DV**. What drugs can be injected intravitreally and what ocular and systemic complications should I look out for? In: Fekrat S, ed. Curbside Consultation in Retina: 49 Clinical Questions. Thorofare, NJ: SLACK Incorporated; 2010:91-95.
18. **Do DV**, Wilker S, Nguyen QD. VEGF Trap-Eye. Retina Pharmacotherapies. Nguyen, Farah, Meiler, Editors, Elsevier, 2010:261-266.
19. **Do DV**, Nguyen QD. Vitreous, retinal, and choroidal biopsy. Retina, 5th Edition, SJ Ryan, Editor, Elsevier/Mosby Publishing; 2012.
20. **Do DV**, Schachat AP. Leukemias and Lymphomas. Retina, 5th Edition, SJ Ryan, Editor, Elsevier/Mosby Publishing; 2012
21. **Do DV** and Haller JA. Coats' disease and retinal telangiectasia. Ophthalmology, 4th Edition. Yanoff and Duker, Editors. Elsevier Publishing; 2012
22. **Do DV**, Nguyen QD. Vitreous, retinal, and choroidal biopsy. Retina, 6th Edition, SJ Ryan, Editor, Elsevier/Mosby Publishing; 2021
23. **Do DV**. Clinical Trialist. Women in Ophthalmology – a comprehensive guide for career and life. Weng and Berrocal, Editors. Springer Publishing, 2021
24. Hasan, M, **Do DV** and Haller JA. Coats' disease and retinal telangiectasia. Ophthalmology, 5th Edition. Yanoff and Duker, Editors. Elsevier Publishing; 2021

Editorial Boards

2009-2017	Retina Physician
2010-2016	New Retina MD Journal Section Editor, The Road to Recertification
2013-2019	Cochrane Eyes and Vision Group
2013-2019	Ophthalmic Surgery Lasers and Imaging Retina

2016 -2022 American Journal of Ophthalmology Case Reports

2020-2022 [Eyewiki](#) (American Academy of Ophthalmology)
Section Editor, Retina

Clinical Trials

Current Research Support from Clinical Trials

1. Phase 3 Multicenter, Randomized, Sham Controlled, Study to Determine the Safety and Efficacy of Renexus® in Macular Telangiectasia Type 2

Sponsor: Lowy Medical Research Institute

Role: Principal Investigator

2. Double-Masked, Randomized, Sham-Controlled, Parallel Group, Multi-Center Study to Assess the Safety and Efficacy of Photobiomodulation (PBM) in Subjects with Dry Age-Related Macular Degeneration (AMD) (LIGHTSITE III)

Sponsor: LumiThera, Inc

Role: Principal Investigator

4. LUMINA: A Phase III, Multicenter, Sham-Controlled, Randomized, Double-Masked Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 µg DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

Sponsor: Santen

Role: Principle Investigator

5. A randomized, double-masked, active-controlled phase 2/3 study of the efficacy and safety of high-dose aflibercept in patients with diabetic macular edema (PHOTON)

Sponsor: Regeneron

Role: Principal Investigator

6. Optic Disc Drusen Research: Collaborative research to study optic disc drusen, it's complications, and identify effective treatments. Principal investigator is Joyce Liao, MD, PhD.

Role: Co-investigator

7. Natural HistOry of Dry Age-RElated Macular DegeneratiOn (OREO: A Prospective Observational Study)

Sponsor: Boehringer Ingelheim

Role: Co-investigator

8. A Phase 2a, Prospective, Multicenter, Randomized, Double-Masked, Sham-Controlled Study to Assess the Safety, Tolerability, and Evidence of Activity of a Single Intravitreal Injection of UBX1325 in Patients with Neovascular Age-Related Macular Degeneration [CA]

Sponsor: Unity Biotech

Role: PI

Previous Clinical Trials (abbreviated list)

1. Title: A Phase III, Multinational, Multicenter, Randomized, Double-Masked, Study Assessing the Safety and Efficacy of Intravitreal Injections of DE-109 for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye (SAKURA Study)

Funding Source: Santen Incorporated

Project Period: 2013-2016

Role: Principal Investigator

2. Title: A Phase 2, Randomized, Active-controlled, Double-masked, Multicenter Study to Assess the Safety and Efficacy of Daily Subcutaneous AKB-9778 Administered for 3 Months, As Monotherapy or Adjunctive to Ranibizumab, in Subjects with Diabetic Macular Edema

Funding Source: Aerpio Therapeutics, Inc.

Project Period: 2014-2016

Role: Principal Investigator

3. Title: A Prospective, Multi-Center, Randomized, Controlled Clinical Trial Designed to Evaluate the Safety and Preliminary Efficacy of V404 PDS in Chronic Noninfectious Uveitis

Funding Source: Forsight Vision4, Inc.

Project Period: 2014-2016

Role: Principal Investigator

4. Title: A Randomized, Double-masked and Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab Administered Subcutaneously every 2 weeks in Patients with Non-infectious, Intermediate, Posterior or Pan-Uveitis (NIU)

Funding Source: Sanofi-Aventis U.S., Inc.

Project Period: 2014-2016

Role: Co-Investigator

5. Title: iDeal Study Reading Center

Funding Agency: Juvenile Diabetes Research Foundation International

Project Period: 2013-2016

Role: Co-Investigator

6. Title: A Phase 2A, Multi-Center, Masked, Randomized, Comparator-Controlled Study Evaluating Isonoptm (Sonepcizumab [LT1009] as either Monotherapy or Adjunctive Therapy to Lucentis, Avastin or Eylea versus Lucentis, Avastin or Eylea Alone for the Treatment of Neovascular Age Related Macular Degeneration (NEXUS)

Funding Agency: Lpath, Inc.

Project Period: 2013-2015

Role: Principal Investigator

7. Title: Sirolimus as a Therapeutic Approach for Uveitis: A Phase 2, Open-label, Randomized Study to Assess the Safety, Tolerability, and Bioactivity of Two Doses of Intravitreal Injection of Sirolimus in Patients with Non-Infectious Uveitis (SAVE-2)

Funding Agency: Santen Incorporated

Role: Co-Investigator

8. UNMC Program of Excellence: Center for Evidence Based Medicine and Comparative Effectiveness Research

Funding Agency: University of Nebraska Medical Center

Role: Co-Investigator

9. Title: Remote Interventions Improving Specialty Complex Care (RIISCC) Geographic Reach: Nebraska Estimated Funding Amount: \$9,993,626 Funding Agency: Centers for Medicare and Medicaid Services Role: Co-Investigator (Principal Investigator: Mandi Constantine, PhD)

10. Title: Longitudinal Evaluation of Geographic Atrophy with Novel Imaging Modalities Funding Agency: Genentech, Inc.
Project Period: 2010-2013
Role: Principal Investigator

11 Title: A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Intravitreal Injections of High Dose Ranibizumab in Subjects with Macular Edema Secondary to Diabetes Mellitus (READ 3 Study)
Sponsor: Juvenile Diabetes Research Foundation
Project Period: 2010-2013
Role: Principal Investigator

12. Title: A Randomized, Multi-center, Phase II Study of the Safety, Tolerability, and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination with Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema with Involvement of the FoveAL Center (the IDEAL Study)
Sponsor: Juvenile Diabetes Research Foundation
Project Period: 2012-2013
Role: Principal Investigator

12. Title: An Exploratory Study of the Safety, Tolerability, and Biological Effect of Intravitreal Administration of VEGF Trap in Patients with Neovascular Age-Related Macular Degeneration
Sponsor: Regeneron, Inc.
Project Period: 2006-2008
Role: Co-Investigator

13. Title: AMD DOC (Detection of Onset of new Choroidal Neovascularization) Study. A multi-center study to evaluate sensitivity of optical coherence tomography and Preferential Hyperacuity Perimeter for detecting onset of new CNV in subjects with high risk non-neovascular AMD.
Sponsor: The Lucy Foundation
Project Period: 2006-2009
Role: Study Chair

14. Title: RIPT (Ranibizumab for Idiopathic Parafoveal Telangiectasia) Study. A pilot study to evaluate intravitreal ranibizumab in parafoveal telangiectasia.
Sponsor: Genentech, Inc.
Project Period: 2006-2008
Role: Co-Investigator

15. Title: VEGF Trap Eye Phase 1 Trial for Diabetic Macular Edema
Sponsor: Regeneron, Inc.
Project Period: 2007-2008

Role: Principal Investigator

16. Title: VEGF Trap Eye Phase 2 Trial for Diabetic Macular Edema: the DA VINCI Study
Sponsor: Regeneron, Inc.
Project Period: 2008-2010
Role: Principal Investigator

17. Title: Phase 1 Study of a Topical ICAM Inhibitor
Sponsor: SARCODE, Inc.
Project Period: 2009-2010
Role: Principal Investigator

18. Title: A Phase II Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Intravitreal Injections of Ranibizumab in Subjects with Macular Edema Secondary to Diabetes Mellitus (READ 2 Study)
Sponsor: Juvenile Diabetes Research Foundation
Project Period: 2006-2013
Role: Co-Investigator

18. Title: Evaluating Optical Coherence Tomography and Fluorescein Angiography in Neovascular Age-Related Macular Degeneration
Sponsor: Genentech, Inc.
Project Period: 2008-2012
Role: Principal Investigator

20. Title: Phase 2 Study of Anti-Factor D for Geographic Atrophy
Sponsor: Genentech, Inc.
Project Period: 2011-2013
Role: Principal Investigator

Professional societies

Alpha Omega Alpha, Honor Medical Society
American Academy of Ophthalmology
Association for Research and Vision Ophthalmology
American Society of Retina Specialists
Macula Society
Retina Society
Women in Retina

Leadership, Service, and Administration (Stanford and National Organizations)

2019- Present	Vice Chair for Clinical Affairs Byers Eye Institute Stanford University School of Medicine
2021-Present	Clinic Chief of Ophthalmology, Stanford Health Care
2017- Present	Physician Improvement Leader for the Byers Eye Institute, Stanford I oversee the Quality/Value/Improvement Projects within our

department and work with colleagues to implement innovative projects to assist faculty, staff, and patients.

2017- Present Quality Council Member, Byers Eye Institute, Stanford

2019- Present Medical Executive Committee, Member Representing Dept of Ophthalmology, Stanford

2019-Present Communications Committee, American Society of Retina Specialists
Member of committee that develops and curates online educational content for the American Society of Retina Specialists

2022-Present Board Member and Treasurer
Women in Retina (WinR)
American Society of Retina Specialists

2020-Present Board Member and Secretary
Women in Retina (WinR)
American Society of Retina Specialists

2021- Present Medical School Applicant Review Committee, Stanford School of Medicine

2017- 2019 Physician Well-Being Committee, Stanford Health Care

2017- Present Resident Education Committee, Byers Eye Institute, Stanford

2017-Present Resident Selection Committee, Byers Eye Institute, Stanford

2017- Present Retina Fellowship Selection Committee, Byers Eye Institute, Stanford

2014-2016 Physician Network Advisory Committee, University of Nebraska Medical Center

2013-2016 Center for Evidence-Based Medicine and Comparative Effectiveness Research (Program of Excellence Awardee), University of Nebraska Medical Center

2013-2016 Graduate Medical Education Committee, University of Nebraska College of Medicine

2013-2016 Program Evaluation Committee, Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences

2013-2016 Clinical Competency Committee, Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences

2013-2016 Director of Residency Training Program, Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences

2013-2016 Director of Carl Camras Center for Innovative Clinical Research, Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences

2013-2016 Vice-Chair for Education, Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences

2013-2016 Residency Selection Committee, Truhlsen Eye Institute, Department of Ophthalmology and Visual Sciences

2012-2013 Head of the Retina Fellowship Training Program, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland

2005-2012 Assistant Head of the Retina Fellowship Training Program, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland

2005-2013 Residency Selection Committee, The Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland

2005-2013 Admissions Committee, The Johns Hopkins University School of Medicine, Baltimore, Maryland

1997-1999 Admissions Committee, University of California San Francisco
School of Medicine

Service at Byers Eye Institute, Department of Ophthalmology

2019- Now Vice Chair for Clinical Affairs
Byers Eye Institute
Stanford University School of Medicine

2021-Present Clinic Chief of Ophthalmology, Stanford Health Care

2017- Now Physician Improvement Leader for the Byers Eye Institute, Stanford
I oversee the Quality/Value/Improvement Projects within our department and work with colleagues to implement innovative projects to assist faculty, staff, and patients.

2019- Present Medical Executive Committee, Member Representing Dept of Ophthalmology, Stanford

2017- Now Quality Council member, Byers Eye Institute, Stanford

2017- Now Resident Clinical Competency Committee, Byers Eye Institute, Stanford

2017- Now Resident Education Committee, Byers Eye Institute, Stanford

2017- Now Residency Selection Committee, Byers Eye Institute, Stanford

2017- Now Retina Fellowship Selection Committee, Byers Eye Institute, Stanford

All Invited Lectures (Since joining Stanford):

1. Angiogenesis Meeting
Bascom Palmer Eye Institute, University of Miami
February 2017
Miami, Florida
“Pharmacokinetics of Aflibercept”
2. Sonoma Eye Meeting
March 2017
“Suprachoroidal Delivery of Triamcinolone for Non Infectious Uveitis”
3. Canadian Ophthalmology Society Annual Meeting
Canadian Retina Society Annual Meeting
June 15, 2017
Montreal, Canada
“Current Concepts in Management of Diabetic Retinopathy”
“Multimodal Imaging in Retina”
4. Angiogenesis 2018 Meeting
Bascom Palmer Eye Institute, University of Miami
February 2019
“KSI-301: A Novel Antibody Biopolymer”
5. Sonoma Eye Meeting
March 2018
“Antibody Biopolymer Conjugates for Extended Durability”

6. Angiogenesis 2019 Meeting
Bascom Palmer Eye Institute, University of Miami
February 2019
“KSI-301: A Novel Antibody Biopolymer”
7. American Academy of Ophthalmology Retina Subspecialty Day 2019
October 2019
“VEGF Inhibitors for the Treatment of Diabetic Retinopathy”
8. American Society of Retina Specialists Annual Meeting 2019
July 2019
“Improvement in Diabetic Retinopathy in Aflibercept Treated Eyes in the VIVID and VISTA Studies”
9. Asian Pacific Vitreo-Retinal Society Meeting 2019
Shanghai, China
“KSI-301: a Novel Antibody Biopolymer Conjugate for Exudative Retinal Diseases”
10. Macula Society Annual Meeting 2020
February 2020
“Ranibizumab for Diabetic Retinopathy”
11. American Society of Retina Specialists Annual Meeting 2020
July 2020
“Meta-analysis of Treatment Regimens for Neovascular Age Related Macular Degeneration”
12. Retina Society Annual Meeting 2020
October 2020
“Safety of Aflibercept”
13. American Academy of Ophthalmology Retina Subspecialty Day 2020
November 2020
“Are VEGF Inhibitors Equal?”
14. Angiogenesis and Exudation Meeting, Bascom Palmer Eye Institute
University of Miami
February 2021
“Update on KSI-301: Novel Antibody Biopolymer Conjugate with Extended Durability – Year 1 Results”
15. Sonoma Eye 2021
January 2021
“Update on Inflammation Associated with Intravitreal Anti-VEGF Medicines”
16. Retina Society Annual Meeting 2021
October 2021
“Should We Be Treating Severe Non Proliferative Diabetic Retinopathy?”
17. Retina Society Annual Meeting 2022
November 2022

“Lightsite Clinical Trial: Photobiomodulation for AMD”

18. American Society of Retina Specialists Annual Meeting 2022
July 2022

“Anatomic Outcomes Based on Baseline Characteristics in the PANOMARA Clinical Trial”

19. American Academy of Ophthalmology 2022
September 2022

“Update on Age Related Macular Degeneration”

21. Jules Gonin Retina Meeting 2022
September 2022

“Update on Aflibercept for Diabetic Retinopathy”

Invited Lectures (National and International before joining Stanford - Abbreviated List)

1. Retina Fellows Forum, 2006-2009
Invited Faculty (I was one of 6 invited faculty members [and the only female faculty] to participate in this national conference which highlights important medical and surgical knowledge for retina fellows currently in their last year of training)
Sponsored by the American Society of Retina Specialists
Location: Chicago, IL
2. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting Fort Lauderdale, Florida, April 30-May 4, 2006
Invited Speaker, Special Interest Group (SIG) for New Treatments in Retina
3. “Systemic Bevacizumab for Choroidal Neovascularization.”
Segundo Congreso de la Sociedad Pan Americana de Retina y Vitreo
Cartagena de Indias, Columbia, May 17-20, 2006
Invited Faculty and Special Guest
“Detecting Neovascular AMD”
“ABCs of OCT”
4. The Second French-American Ophthalmological Symposium
New York, New York, June 2-3, 2006
Invited Faculty
“Relationship Between Hemoglobin A1c and Persistent DME”
5. The 90th Annual Pacific Coast Oto-Ophthalmological Society Meeting
Cabo San Lucas, Mexico, June 23-27, 2006
Invited Faculty
“DME Treatment Algorithm”
“AREDS Simple Clinical Scale”
6. The 2006 Annual Meeting of the American Association of Diabetes Educators
Los Angeles, California, August 8-9, 2006
Invited Faculty

“Molecular Pathways of Diabetic Retinopathy: Where Are We Going with Therapy in the 21st Century”

7. 2006 Macula in Paris Conference
Paris, France, September 5-6, 2006
Invited Faculty
“Myocardial Infarction and Cerebrovascular Accident in AMD Patients”
8. 2006 Annual Meeting of the Philippine Academy of Ophthalmology
Manila, the Philippines, November 24-28, 2006
Invited Speaker
“Detecting New Onset CNV”
9. The 2007 Retinal Physician Symposium
Fort Meyers, Florida, April 11-14, 2007
Invited Faculty
“Treatment algorithm for DME”
10. Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Fort Lauderdale, Florida, May 6 – May10, 2007
Invited Speaker, Special Interest Group (SIG)
“Ranibizumab for Vein Occlusion”
11. XXVIII Congreso Pan Americana de Oftalmologia
Cancun, Mexico, May 30 – June 4, 2007
Invited Speaker
“OCT for evaluating macular disease”
12. 2007 Annual Juvenile Diabetes Research Foundation
Maryland Chapter
Baltimore, MD, June 2007
Featured Invited Speaker
“**Ranibizumab** for **Edema** of the **mAcula** in **Diabetes**: A Phase 2 Study –
the READ 2 Study. What is Ahead for Patients with Diabetic Macular Edema?”
13. The Third French-American Ophthalmological Symposium
Boston, Massachusetts, June 15-16, 2007
Invited Faculty
“AREDS Simple Clinical Scale for AMD”
14. First Annual Geneva Uveitis Society Conference
Geneva, Switzerland, September 12-13, 2007
Invited Faculty
“Diagnostic Vitrectomy”
15. 2007 Retina Subspecialty Day at the Annual Meeting of the American Academy of
Ophthalmology
New Orleans, Louisiana, November 9-13, 2007
Invited Speaker
“Systemic Safety of VEGF Inhibition”

16. 2008 Les Journees Ophtalmologiques de L'Universite Laval (JOUL)
Quebec, Canada, February 7-8, 2008
Invited Speaker
"Treatment Algorithm for Diabetic Macular Edema"
"AMD Severity Scales and Detecting New Onset Neovascular AMD"
17. 2008 Angiogenesis, Exudation, and Degeneration Meeting
Bascom Palmer Eye Institute, University of Miami
Miami, Florida, February 22-23, 2008
Invited Speaker
"Updates on the READ 2 Study"
18. International Society of Ocular Pharmacotherapy and Therapeutics
7th Meeting
Budapest, Hungary, February 28-March 2, 2008
Invited Speaker
"Ranibizumab for Diabetic Macular Edema"
"Bevacizumab for Vein Occlusion"
"VEGF Trap for Diabetic Macular Edema"
19. Aspen Retinal Detachment Society Annual Meeting
Aspen, Colorado, March 3-6, 2008
Invited Speaker
"Fluorescein Angiography vs OCT for Neovascular AMD"
"Does 25 gauge Vitrectomy Increase the Risk for Endophthalmitis?"
20. 33rd Congress of the Brazil Retina Society
Salvador, Brazil, April 3-5, 2008
Invited Speaker
"AREDS Simplified Scale"
"Systemic Safety of VEGF Inhibition"
"Does 25 gauge Vitrectomy Increase the Risk for Endophthalmitis?"
21. Maryland Society of Eye Physicians and Surgeons Annual Meeting
Invited Speaker
May 2008
Update on Neovascular AMD
Westin Hotel, BWI Airport
22. Retina Physician Symposium Annual Meeting
Naples, FL
May 2008
Invited Speaker
"Update on DRCR"
23. Korean Retina Society
Yonsei University Retina Congress
Seoul, Korea
June 26-29, 2009
"Update on Treatment of CNV in Pathologic Myopia"

24. World Congress of Ophthalmology
June 29-July 2, 2009
Hong Kong
Invited Speaker
VEGF Inhibition in AMD and DME
25. Baltimore Medical Society
Invited Speaker
September 2008
“Changing Treatment Paradigms in Diabetic Retinopathy”
26. 2008 Retina Subspecialty Day at the Annual Meeting of the American Academy of Ophthalmology
Atlanta, Georgia, November 7-8, 2008
Invited Speaker
“Update on Ranibizumab for Diabetic Macular Edema”
27. 2008 Uveitis Subspecialty Day at the Annual Meeting of the American Academy of Ophthalmology
Atlanta, Georgia, November 7-8, 2008
Invited Speaker
“Diagnostic Vitrectomy”
28. Macula of Paris
January 2009
“Ranibizumab for Diabetic Macular Edema”
29. Sarasota Retina Symposium 2009
Sarasota, FL
Invited Speaker
“Update on Focal Laser For DME”
30. Retina Physician Symposium Annual Meeting
Bahamas
Invited Speaker
March 25-28, 2009
“Update on DRCR”
“Update on the READ 2 Study”
31. Yale University School of Medicine, Retina Meeting
New York
April 3, 2009
Invited Speaker
“VEGF inhibitors for Vein Occlusion
32. International Society of Ocular Inflammation
Prague
May 2009
Invited Speaker
“Laser for Diabetic Macular Edema”

33. The Fourth French American Ophthalmology Congress
New York, June 5, 2009
Invited Speaker
“Advances in Vitrectomy Surgery”
34. Advances in Retinal Therapy (ART)
Medical University of Vienna
Vienna, Austria
November 14, 2009
Invited Speaker
“Surgery for Post-Vitrectomy Cataract”
35. Euretina Winter Meeting
Vienna, Austria
November 15, 2009
Invited Speaker
“Anti-VEGF and Ischemia”
36. King Khaled Eye Surgery Hospital (KKESH)
Saudi Arabia
December 2009
Grand Rounds
Invited Speaker
“VEGF Inhibitors for Diabetic Macular Edema”
37. International Society of Ocular Pharmacotherapy (ISOPT) Annual Meeting
December 2009
Invited Speaker
“VEGF Trap-Eye for Diabetic Macular Edema”
“Ranibizumab for Diabetic Macular Edema: 1 Year Results for the READ 2 Study”
38. Angiogenesis 2010
February 22, 2010
Bascom Palmer Eye Institute
University of Miami School of Medicine
Invited Speaker
“Results of the DA VINCI Study: VEGF Trap-Eye for Diabetic Macular Edema”
39. **William Evans Bruner, MD Lecture** at Case Western University, Cleveland, Ohio
Department of Ophthalmology
Invited Speaker
April 24, 2010
“Current Treatments for Diabetic Macular Edema”
40. Kansas University EyeCon Ophthalmology Conference
Invited Speaker
Kansas City, Kansas
May 8, 2010
“Update on the READ 2 Study and VEGF Blockade for Diabetic Macular Edema”
“Update on Potential Treatments for Dry Age Related Macular Degeneration”

41. 2010 Uveitis Subspecialty Day at the Annual Meeting of the American Academy of Ophthalmology
Chicago, IL, October 16, 2010
Invited Speaker
“Retinal and Choroidal Biopsy Techniques for Posterior Uveitis”
42. 2010 Retina Subspecialty Day at the Annual Meeting of the American Academy of Ophthalmology
Chicago, IL, October 15, 2010
Invited Speaker
Age-Related Macular Degeneration – Panel Discussion
43. 2010 Annual Meeting of the American Academy of Ophthalmology
Chicago, IL, October 15, 2010
Paper Presentation
“VEGF Trap Eye for Diabetic Macular Edema: Primary Outcome Results of the DA VINCI Study”
Awarded “Best Paper” in Retina Section
44. 2010 Annual Meeting of the American Academy of Ophthalmology
Chicago, IL, October 15, 2010
Paper Presentation
“Phase 1 Study of Anti-Factor D for Geographic Atrophy”
45. 2010 Hospital Centro Ophthalmology Congress
Invited Speaker
Lisbon, Portugal, November 5 2010
“Vitreoretinal Surgery in Uveitis”
46. 2011 Macula of Paris
Invited Speaker
Paris, France, January 14, 2011
“Potential Treatments for Geographic Atrophy”
47. 2011 Wills Eye Hospital Macula Meeting, Thomas Jefferson University
Invited Speaker
Philadelphia, PA, January 28, 2011
“VEGF Trap-Eye for Diabetic Macular Edema”
48. **International Society for Prevention of Blindness** Lecturer at
2011 Illinois Association of Ophthalmology and Chicago Ophthalmological Society
Annual Joint Conference
Invited Speaker
Chicago, IL, February 4, 2011
“Current Management of Diabetic Macular Edema”
“Update on Management of Macular Edema in Vein Occlusion”
49. 2011 Angiogenesis Meeting, Bascom Palmer, University of Miami Miller School of Medicine
Invited Speaker
Miami, FL, February 12, 2011

“VEGF Trap-Eye for Diabetic Macular Edema: month 12 Results”

50. Retinal Physician Symposium

Invited Speaker

February 26, 2011

“DA VINCI Study: VEGF Trap-Eye for Diabetic Macular Edema”

“Update on Diabetic Retinopathy Clinical Research Network Clinical Trials”

Las Vegas, NV

51. The Fifth French-American Ophthalmological Symposium

Invited Speaker

June 18, 2011

“Update on Management of Diabetic Macular Edema”

Montreal, Canada

52. Southeast Ophthalmology Conference

Invited Speaker

July 22-23, 2011

“Update on Dry Age-Related Macular Degeneration”

“Update on Diabetic Macular Edema”

Destin, Florida

53. 2011 Annual Meeting of the American Academy of Ophthalmology

Orlando, FL, October 2011

Paper Presentation

“DA VINCI Study: 1 year Outcomes of VEGF Trap-Eye for Diabetic Macular Edema”

54. Macula 2012

Invited Speaker

“Update on Aflibercept for Diabetic Macular Edema”

New York City, NY

55. Ohio State University

Managing Diabetic Retinopathy

The Albert D. Frost Memorial Lecture

“Strategies for Management and Treatment of Diabetic Macular Edema”

March 2-3, 2012

Columbus, Ohio

56. Asian Pacific Ophthalmology Society

Invited Speaker

“Update on Steroids for Retinal Vein Occlusion”

“Update on Treatments for Neovascular AMD”

April 2012

Busan, Korea

57. Angiogenesis Meeting

Bascom Palmer Eye Institute, University of Miami

February 2013

Miami, Florida

Invited Speaker

“Update on Aflibercept for Diabetic Macular Edema”

58. The Sixth French-American Ophthalmological Symposium
San Francisco, April 18, 2013

Invited Faculty

“Management of Diabetic Macular Edema”

“Wide-Field Imaging for Uveitis”

59. Chicagoland Midwest Retina Update

May 18, 2013

Invited faculty

“Implications of CATT Study on Clinical Practice”

“Laser in Diabetic Macular Edema”

60. 30th Annual Wake Forest Eye Center Conference

Winston – Salem, North Carolina

Invited Faculty

“Current Management of Diabetic Macular Edema”

“Is there Still a Role for Laser?”

May 31, 2013

61. University of California San Francisco Medical School Ophthalmology Department

Invited Professor for Grand Rounds

“Role of anti-VEGF Agents in Management of Diabetic Macular Edema”

September 12, 2013

62. 2013 Retina Subspecialty Day at the Annual Meeting of the American Academy of
Ophthalmology

New Orleans, LA

November 15, 2013

Invited Speaker

Primary Results of the VIVID/VISTA Trials of Aflibercept for Diabetic Macular Edema

63. 2014 Retina Subspecialty Day at the Annual Meeting of the American Academy of
Ophthalmology

Chicago, IL

October 17, 2014

Invited Speaker

Two-Year Results of VIVID/VISTA Trials of Aflibercept for Diabetic Macular Edema

64. Angiogenesis Meeting

Bascom Palmer Eye Institute, University of Miami

February 2015

Miami, Florida

Invited Speaker

“What Have We Learned About Aflibercept in Diabetic Retinopathy”

65. 7th French American Ophthalmology Symposium (Section Chair)

Monte-Carlo, Monaco

June 25 – 26, 2015

Is Retina Surgery Helpful In Uveitis?

66. 2015 Retina Subspecialty Day at the Annual Meeting of the American Academy of Ophthalmology

Las Vegas

Invited Speaker

Retina Vein Occlusion : Expert Panel Discussion

67. Angiogenesis Meeting

Bascom Palmer Eye Institute, University of Miami

February 2016

Miami, Florida

Invited Speaker

“Update on Aflibercept for Diabetic Macular Edema and Diabetic Retinopathy”

Teaching Activities

Clinical and Classroom Instruction

2017-Present

Retina lecturer at Bay Area Ophthalmology Course sponsored by Stanford

Role: Organize and teach on the subject of age-related macular degeneration at this annual CME course

2019-2020

Age-Related Macular Degeneration Lecture

Role: Organize and taught Undergraduate Students at Stanford University on the topic of AMD

2017-Present

Retina Division Education Co-Director

Role: Organize and work with faculty to ensure the Educational Activities for the Retina Division including overseeing the retina didactic lectures for residents, and journal club for retina fellows/residents.

Supervise and teach retina fellows in clinic and operating room

2017-Present

Retina Rotation for Ophthalmology Residents at Stanford

Role: Faculty

2017-Present

Retina Clinic Rotation and Retina Operating Room Rotation for Retina Fellows at Stanford

2013-2016

Retina Lectures (3 hours per month) for Ophthalmology Residents and Fellows

Truhlsen Eye Institute

University of Nebraska College of Medicine

Role: Faculty

2014-2016

Ophthalmology 1-Week Didactic Course and Case-Based Clinical Discussions for 2nd Year Medical Students, University of Nebraska College of Medicine
Role: Faculty Supervisor

2013-2016

Retina Rotation for 3rd and 4th Year Medical Students, University of Nebraska College of Medicine
Role: Faculty

2013-2016

Retina Rotation for Ophthalmology Residents and Fellows
University of Nebraska College of Medicine
Role: Faculty

CONTINUING MEDICAL EDUCATION COURSES - LEADERSHIP (MOST RECENT)

Stanford Retina Innovation Summit

2020-Present

Co-Founder, Co-Organizer, and Faculty Lecturer

National meeting started by myself and 3 other Stanford retina faculty (Prithvi Mruthyunjaya, MD, Stephen Smith, MD, and Quan Dong Nguyen, MD) that discusses innovation in retina including late-breaking news from clinical trials, new data for clinical management of retinal diseases, collaborating with industry, and understanding regulatory rules.

Sonoma Eye

2017-Present

Planning Committee

Retina Section Co-organizer and Lecturer

National, annual meeting that discusses the latest topics in ocular inflammation and eye diseases. I plan the retina section and organize international faculty to participate.

CONTINUING MEDICAL EDUCATION COURSES (Prior)

April 2013

Symptomatic Vitreomacular Adhesion by Vindico

Role: Faculty lecturer

Location: Chicago, IL

May 2013

Neovascular AMD Update sponsored by Advanced Studies in Ophthalmology, Johns Hopkins Medicine

Role: Faculty lecturer

Location: Seattle, WA

November 2013

Retinal Vein Occlusion Management sponsored by Advanced Studies in Ophthalmology,
Johns Hopkins Medicine
Role: Faculty lecturer
Location: New Orleans, LA

November 2013
TRUST Symposium: Update on Uveitis Management sponsored by MedEdicus
Role: Faculty lecturer
Location: New Orleans, LA

November 2013
Neovascular AMD Update sponsored by Advanced Studies in Ophthalmology, Johns
Hopkins Medicine
Role: Chair and Faculty lecturer
Location: New Orleans, LA

May 2013
20th Annual Gifford Truhlsen Day Ophthalmology Course, Truhlsen Eye Institute, UNMC
Role: Co-Director
Location: Marriott Hotel, Omaha, NE

Retina 2014 at Hawaiian Eye sponsored by Vindico
Role: Faculty Lecturer
Location: Kauai, HI

May 2014
Chicagoland Retina Update CME Course
Role: Faculty Lecturer
Location: Chicago, IL

June 2014
21st Annual Gifford Truhlsen Day Ophthalmology Course, Truhlsen Eye Institute, UNMC
Role: Co-Director
Location: Michael Sorrell Center, UNMC, Omaha, NE

July 2014 to November 2014
Update on Management of Age-Related Macular Degeneration, Diabetic Macular Edema,
and Retinal Vein Occlusion
Role: Co-Chair and Faculty lecturer
Location: Chicago, IL; New York, NY; San Francisco, CA; Boston, MA

August 2014
Current Management of Diabetic Macular Edema and Diabetic Retinopathy
Role: Co-Director
Location: San Diego, CA (in conjunction with the American Society of Retina Specialists
Annual Meeting)

August 2014
Diabetic Eye Diseases: Reducing the Burden Through Synergistic Treatments
Role: Faculty

Location: San Diego, CA (in conjunction with the American Society of Retina Specialists Annual Meeting)

February 2015

Lessons Learned from VIVID and VISTA Studies of Aflibercept
Angiogenesis, Exudation, and Atrophy Meeting
Bascom Palmer Eye Institute
University of Miami School of Medicine
Role: Faculty
Location: Miami, FL

June 2015

22nd Annual Gifford Truhlsen Day Ophthalmology Course, Truhlsen Eye Institute, UNMC
Role: Co-Director
Location: Michael Sorrell Center, UNMC, Omaha, NE

November 2015

TRUST Symposium: Update on Uveitis Management sponsored by MedEdicus
Role: Faculty lecturer
Location: Las Vegas

November 2015

Current Management of Diabetic Macular Edema
Role: Co-Director
Location: Las Vegas (in conjunction with the AAO Meeting)

January 2016

Retina 2016 (Hawaiian Eye)
Role: Faculty

2017

Retina Forum 2017: Optimizing Management of Retinal Vascular Diseases
National CME Course
Role: Co-chair

Mentoring Activities:

Mentoring Faculty at Stanford University

Carolyn Pan, MD: Associate Professor of Ophthalmology

Caroline Ann Fisher, MD: Associate Professor of Ophthalmology

Andrea Kossler, MD: Assistant Professor of Ophthalmology

Euna Koo, MD: Assistant Professor of Ophthalmology

Sophia Wang, MD: Assistant Professor of Ophthalmology

Robert Chang, MD: Associate Professor of Ophthalmology

Mentoring Retina Fellows at Stanford University

2017	Margaret Greven, MD	(Faculty, Wake Forest University, NC)
2018	Stephen J. Smith, MD	(Faculty, Stanford University, CA)
2019	Zachary Bodnar, MD	(Private Practice, Las Vegas, NV)
	Peter Tang, MD, PhD	(Private Practice, Minneapolis, MN)
2020	Natalia Callaway, MD	(Adjunct Faculty, Stanford)
2020-now	Kapil Mishra, MD	
	Huy Nguyen, MD	
	Nadim Rayess, MD	
	Suzanne Michalak, MD	
	Charles DeBoer, MD	
2022-now	Karen Wai, MD	
	Austen Knapp, MD	
2023-now	Lucie Guo, MD, PhD	
	Jared Sokul, MD	

Mentoring Residents at Stanford University

2016-2017	Matthew Powers, MD	
2017-2019	Ryan Shields, MD	
	Cassie Ludwig, MD	
	Laura Huang, MD	
2019- Now	Natacha Villegas, MD	
	Malini Veerappan, MD	
	Jong Park, MD	
	Jose Davilla, MD	
2020- Now	Mohammed Hassan, MD	
	Ahmad Al-Moujahed, MD, PhD	
	Arthur Brant, MD	

Mentoring Medical Students at Stanford University

2019-Now	Angela Li (4 th year med student – matched at Duke for Ophthalmology)
2020-Now	Mary-Grace Reeves (4 th year med student – matched at Washington University for Ophthalmology)
2020-Now	Tatiana Rosenblatt (4 th year med student – matched at Harvard for Ophthalmology)
2021-Now	Arthur Brant (4 th year med student – matched at Stanford for Ophthalmology)
2021-Now	Henry Bair, (3 rd year med student)
2021-Now	Christine Xu, (3 rd year med student)
2022-Now	Samuel Cohen (4 th year med student)
2022-Now	Jessica Hampton (4 th year med student)

Mentoring Retina Fellows at University of Nebraska Medical Center

2015	William Rhoades, MD	(Private Practice, Ann Arbor, Michigan)
------	---------------------	-----------------------------------------

2014 Loren Jack, MD (Private Practice, Spokane, WA)

Mentoring Residents at University of Nebraska Medical Center

2017 Keegan Harkins, MD (Private Practice, NE)
2016 R. Joel Welch, MD (Private Practice, Spokane, WA)
2016 Jonathan Crews, DO (Private Practice, MO)
2015 Christy Benson, MD (Private Practice, Des Moines, IA)

Mentoring Retina Fellows at The Wilmer Eye Institute, Johns Hopkins University School of Medicine

2012 Syed Mahmood Shah, MD (Faculty, University of Pittsburgh)
Joanna Oda, MD (Kaiser, San Francisco, CA)
Claudia Krispel, MD, PhD (Private Practice, NV)
2010 Adam Wenick, MD (Faculty, Johns Hopkins University)
2008 Akrit Sodhi, MD (Faculty, Johns Hopkins University)
Margaret Chang, MD (Private Practice, CA)
Ala Moshiri, MD, PhD (Faculty, UC Davis)
2007 Rahul Khurana, MD (Private Practice, Mountain View, CA)
2006 Sayjal Patel, MD (Naval Hospital, San Diego, CA)

Mentoring Residents at The Wilmer Eye Institute, Johns Hopkins University School of Medicine

2012 - J. Peter Campbell, Connie Chan, Christina Weng

2011 - Bryn Burkholder, Fasika Woreta

2010 - Ali Moshiri, Shameema Sikder, Derek Welsbie, Adam Wenick

2009 - Divya Srikumaran

2008 - David Baranano, Akrit Sodhi

2007 - Holly Hindmann, John Koo, Parag Parekh, Mark Walsh

2006 - Margaret Chang, Pradeep Ramulu, Leejee Suh, Homayoun Tabandeh, Henry Wiley
